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Effects of Long-Term Administration of Caffeine in a
Mouse Model for Alzheimer’s Disease
William Schleif
ABSTRACT
A recent epidemiological study suggested that higher caffeine intake reduces the
risk of Alzheimer’s disease (AD). Caffeine, a widely consumed stimulatory drug, is a
non-selective adenosine receptor antagonist that has been shown to increase plasma
adenosine levels in rodents. To determine any long-term protective effects of caffeine in a
controlled longitudinal study, caffeine was added to the drinking water of APPsw
transgenic (Tg) mice between 4 and 9½ months of age, with behavioral testing done
during the last 6 weeks of treatment. The average daily intake of caffeine per mouse (1.5
mg) was the human equivalent of 5 cups of coffee/day. Across multiple cognitive tasks
of spatial learning/reference memory, working memory, and recognition/identification,
Tg mice given caffeine (Tg+Caff) performed significantly better than Tg control mice
and similar to non-transgenic controls. Discriminant Function Analysis involving
multiple cognitive measures clearly showed the superior overall cognitive performance of
Tg+Caff mice compared to Tg controls. Analysis of Aβ in the hippocampus by ELISA
revealed Tg+Caff mice had significantly less soluble Aβ1-40 and insoluble Aβ1-42. In a
follow-up study involving neurochemical analysis only, caffeine was added to the
drinking water of 17 month old APPsw mice for 18 days. In this study, Tg+Caff mice also
vi

showed a significant reduction of insoluble Aβ1-42 in the hippocampus. In contrast to the
reduced extracellular brain levels of adenosine in Tg controls, caffeine treatment
normalized brain adenosine levels in Tg mice to that of non-transgenic controls. Analysis
of amyloidogenic secretase activity revealed the reduction in Αβ is likely because of a
reduction in γ−secretase activity as a result of increased SAM silencing of PS1
expression. This study suggest that a modest, long-term caffeine intake of approximately
500 mg per day (5 cups of coffee) may reduce considerably the risk of AD by decreasing
amyloidogenesis.
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I. Alzheimer’s Disease
With exponential growth in the population of aged individuals in industrialized
countries comes the increasing prevalence of age-related disorders. Foremost amongst
these disorders is Alzheimer’s disease (AD), which is currently the leading cause for
dementia in the elderly and afflicts an estimated 4.5 million people in the United States
alone. This number is expected to triple over the next fifty years if a cure is not found
(Hebert et al., 2003). The onset of Alzheimer’s is as tragic as it is devastating;
progressively disrupting areas of the brain responsible for memory and motor skills that
ultimately leave the patient comatose and unable to communicate or relate with their
environment before they succumb to death. This continual decline of the patient’s
lifestyle leaves them in a state that is a strain on their family and is costly to society.
Behavior Characterization
The initial onset of AD is often times difficult to pinpoint. During the latent
period of the disease, the underlying disruptions in normal brain physiology begin to
occur decades before any cognitive decline is noticed. Some patients develop a condition
termed MCI (Mild Cognitive Impairment), which is characterized by the progressive
decline of short-term memory and indicates a substantial risk for developing AD. An
estimated 10-15% of MCI patients progress into AD per year, yet it is also worth
mentioning that not all MCI subjects develop AD (Petersen et al., 2001). MCI represents
a transitional state where patients have a noticeable decline in memory different from that
1

of normal aging but are not yet diagnosable as having AD. The short-term memory
impairment found in MCI is similar to AAMI (Age-Associated Memory Impairment), but
cognitive testing can distinguish between the two. Some MCI patients exhibit
neuropsychiatric symptoms as well. A recent case study found over 30% of MCI patients
exhibited symptoms of depression, aggression, anxiety, apathy and irritability. These
symptoms follow a similar trend seen in early AD patients and may serve as a clinical
indicator of MCI severity (Feldman et al., 2004).
Early AD is marked by a moderate loss in working memory that is frequently
accompanied by depression and the symptoms mentioned earlier. Typically language
difficulties also appear with the patient struggling with tests that involve word-finding
and recall. Patients progress into moderate AD when the severity of these symptoms
increase. In addition to a significant decrease in short term memory, the language
difficulties seen in early AD worsen. Moderate AD patients often times create spatially
disordered writing and rely on simpler grammatical sentences to express themselves
(Forbes et al., 2004). Long term memory loss also develops, and moderate AD patients
are prone to wandering and hallucinations as well. The progressive and debilitating
decline in cognition eventually leads to the nearly absolute loss of intellect in the
advanced stage of AD preceding death. The advanced stage of AD also sees the initial
deterioration of motor and sensory skills. Patients in this stage live in a vegetative,
bedridden state, unable to care for themselves in any function.
Pathological Characterization
The prominent lesions characteristic of AD brain pathology, neuritic plaques and
neurofibrillary tangles, were first described by Alois Alzheimer in 1906 but the exact
2

chemical compositions of these lesions were only discovered in the past four decades.
The extracellular neuritic plaques, primarily found in the cerebral cortex and
hippocampus, are composed mainly of amyloid β−peptide (Aβ), a protein that
accumulates in various degrees during normal aging. Several genetic mutations affect the
onset of AD by increasing the rate of Aβ production, through mechanisms that will be
discussed later. Neurofibrillary tangles consist of intracellular paired helical filaments
that are left behind as “tombstones” when neurons degenerate.
Aberrant processing of the amyloid precursor protein (APP) leads to the two
forms of Aβ found in neuritic plaques that differ in their amino acid lengths. Aβ42, the
principal component of the core in neuritic plaques, is more susceptible to aggregation
than the slightly smaller form of Aβ40 (Selkoe, 2001). Recognized as a potential
precursor to neuritic plaques, diffuse plaques are composed solely of Aβ42 and generally
lack any signs of dystrophic neurons. These diffuse plaques are found in significant
numbers in the typical areas associated with AD but also appear in brain areas that will
never develop mature neuritic plaques. Diffuse plaques are also found in the brains of
healthy patients that never show any signs of dementia. Aggregation of Aβ40 with Aβ42
leads to the more compact, fibrillar neuritic plaques associated with AD.
The accumulation of fibril Aβ in the extracelluar space activates microglia within
and surrounding neuritic plaques, which attempt to clear Aβ by phagocytosis and release
free radicals and the cytokines IL-1β and TNF-α (Schubert et al., 2000). Astrocytes are
found in a concentric ring around the cores of mature plaques, and are activated by the
proinflammatory cytokines released by microglia. Astrocytes expedite the rate of amyloid
3

deposition and plaque formation by releasing the inflammatory proteins α1antichymotrypsin (ACT) and apolipoprotein ε (APOE) (Potter et al., 2001). Dystrophic
neurites are also found amid mature amyloid deposits, likely as a result of the free
radicals and inflammatory mediators released by microglia and astrocytes. This
neuroinflammatory cascade that results from the accumulation of Aβ forms the central
tenant of the amyloid hypothesis as the causative agent for the cognitive decline seen in
AD.
Neurofibrillary tangles (NFT) accrue when the microtubule-associated protein tau
is phosphorylated by intracellular kinase(s). The hyperphosphorylation of tau causes it to
uncouple from microtubules and form intracellular paired helical filaments (PHF) that
constitute the molecular makeup of NFTs. The subsequent formation of neurofibrillary
tangles from PHFs disrupts normal cell trafficking and may lead to neuronal death.
Neurofibrillary tangles in AD are typically found in limbic and association cortices of the
brain, often times in association with mature amyloid plaques (Selkoe, 2001). Although
NFTs are considered a pathological hallmark of AD, they are also associated with several
other neurodegenerative diseases and occasionally a late-stage AD patient may exhibit
low levels of these tangles upon autopsy.
Also associated with the insidious nature of AD is a significant decline in
synapses between neurons, as well as the atrophy of neuronal populations in the cerebral
cortex and hippocampus. Axonal transport is crucial for synapse viability and
accumulation of β−amyloid has been shown to inhibit fast axonal transport in cultured rat
neurons (Hiruma et al., 2003), giving a plausible explanation for the significant loss of
synapses seen in AD. Exposure of human cortical neurons to β−amyloid in vitro also
4

disrupts calcium regulation, leading to an increase in intracellular calcium stores that may
enhance neuronal loss via glutamate-induced excitotoxicity (Mattson et al., 1992). This
combined loss of synapses and neurons leads to a progressive loss of neurotransmitter
systems that are responsible for both short and long term memory, reflecting the
behavioral symptoms seen in AD.
Genetics of Alzheimer’s Disease
The two types of Alzheimer’s disease, sporadic and familial, differ only in the age
of onset and share similar pathological and behavioral hallmarks. The sporadic form of
AD typically has an age of onset over 65 years and represents the majority (>95%) of
confirmed Alzheimer’s patients. Usually the sporadic, or late-onset, form of AD has an
unidentifiable cause aside from the possible presence of various risk factors. Patients with
a genetic disposition to develop AD represent the familial form and constitute only a
small percentage of all AD cases. These patients may be diagnosed with AD as early as
their thirties, and no later than their sixties, depending on the nature of the mutation.
Familial AD, or FAD, is linked to autosomal-dominant mutations in three causative genes
of interest. Each of these mutations disrupts the normal processing of APP, resulting in
increased production of β−amyloid species.
The APP gene is located on chromosome 21, and was initially linked to AD due
to the similar neuropathology between AD and the genetic disorder trisomy 21, where the
extra copy of APP leads to its increased expression and deposition of Aβ (Hardy and
Selkoe, 2002). APP is a transmembrane protein with a long extracellular N-terminus and
a much shorter cytoplasmic C-terminus. During normal APP processing, the protease
α−secretase cleaves APP in the middle of the Aβ domain generating non-amyloidogenic
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APP fragments. The less common proteolytic cleavage of APP by β− and γ−secretases
generates the β−amyloid species found in diffuse and neuritic plaques (Zekanowski et al.,
2004). The FAD mutations linked to the APP gene change APP processing so
that β− and γ−secretases are more likely to cleave APP and produce amyloidogenic
fragments, thus accelerating the onset of the disease.
Specific mutations in the APP gene were only discovered in the past decade. A
double missense mutation in the 670 and 671 amino acids of APP was isolated from
several Swedish families that exhibited early onset of AD. This double point mutation
directly favors the cleavage of APP by β−secretase and increases levels of Aβ40 and Aβ42
(Mullan et al., 1992). Additional missense mutations in the APP gene have also been
identified from families of other nationalities that increase the likelihood of γ−secretase
cleavage. In particular, a mutation at amino acid 717 of APP was found in a London
family. This mutation increases the cleavage of APP by γ−secretase and raises the levels
of Aβ42, the β−amyloid species that is especially prone to aggregate.
Mutations in the APP gene are relatively rare however, and subsequent genetic
screening of early onset AD patients found that the majority of FAD cases can be linked
to missense mutations in a presenilin gene, PS1. Rarer FAD cases are seen with
mutations in another presenilin PS2. Located on chromosomes 14 and 1 respectively,
missense mutations in these genes have been linked to FAD cases in hundreds of families
worldwide. The exact molecular actions of the presenilin genes have been difficult to
ascertain, but it is widely accepted that they influence the γ−secretase cleavage site on
APP. It is therefore not surprising that mutations in the presenilins linked to FAD
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increase γ−secretase activity, leading to elevated levels of Aβ42 (Tandon and Fraser,
2002). Patients with presenilin mutations linked to FAD exhibit a 1.5 -to 3-fold increase
in neuritic plaques compared to late-onset AD cases (Selkoe, 2001). In addition to being
the most common cause of FAD, mutations in the PS1 gene also lead to the earliest age
of onset and most aggressive form of the disease.
Diagnosis of Alzheimer’s Disease
The importance of diagnosing AD at its earliest stage is critical because of its
implications in the efficacy of the limited pharmaceuticals and treatments currently used
to treat AD. Diagnosing any form of Alzheimer’s disease with complete certainty is
nearly impossible however until the patient dies and an autopsy can be performed to
identify the pathological hallmarks of AD discussed earlier. There are difficulties in
recognizing the initial manifestations of Alzheimer’s symptoms and differentiating
between the cognitive decline associated with aging and other diseases that cause
dementia. Often times the initial diagnosis of AD is made only after other forms of
dementia are eliminated and at this point diagnosis is probable at best. Recent work has
failed to yield a test battery that can distinguish definitively between the cognitive decline
of normal aging, other forms of dementia, and the initial clinical manifestations of early
Alzheimer’s disease but many recent advances have increased the accuracy in diagnosing
AD in more advanced cases.
Clinical diagnosis of AD is dependent on several criteria: gradual onset of
dementia in the absence of other potential dementia-causing disorders between 40 -90
years of age, impaired daily activities, behavioral alterations, family history,
neuroimaging, and several biological markers. Some patients have relatively intact daily
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functioning with cognitive deficits without full-blown dementia. These people fall into
the broader categories of MCI, cognitive impairment no dementia, questionable
dementia, isolated memory impairment and minimal AD (Nestor et al., 2004).
Dementia is diagnosed after a poor score on the Mini-Mental State Examination
(MMSE), a test given during a clinical evaluation that can reveal a decline in memory.
Other cognitive deficits seen in word naming and calculations are also seen after further
screening. Tests are conducted to rule out common potential causes of dementia such as a
vitamin deficiency, hyperthyroidism, neurosyphilis, or stroke before a diagnosis of
probable AD is made. Additional support for an AD diagnosis may come from a positive
family history, especially if AD is present in first-degree relatives. DNA diagnostic
testing can confirm a familial basis of the disease and is useful for screening the risk of
family members who are asymptomatic. Commercial tests are readily available for the
more common causative mutations in the presenilin genes and for variations in the APOE
gene that may increase susceptibility for sporadic AD, yet a clinical test for APP remains
undeveloped. The presence of one or two copies of the ApoE4 allele with accompanying
dementia also lends support for a more definitive AD diagnosis, as this particular allele
confers an increased risk to developing the disease by reasons that will be discussed later
(Gaskell et al., 2004).
Genetic confirmation of AD using clinical DNA testing is accurate, yet it is
limited in its application by the relatively small number of AD cases that have a familial
basis. Therefore, the development of biological markers that can contribute to the early
diagnosis of sporadic AD is underway but has yet to reach widespread clinical
application. Currently the most widely used markers for AD are amyloid-β proteins and
8

both tau and hyperphosphorylated tau protein levels collected from the CSF, but there are
drawbacks to using either marker. AD patients are characterized by low levels of Aβ42 in
both blood plasma and the CSF, but there is significant variability in Aβ42 levels between
individuals. Low levels of Aβ42 may also be found in other diseases, such as depression.
This makes it difficult to set the standard range for clinical AD in the overall population
using this marker, yet longitudinal studies on individuals are useful (Sobow et al., 2004).
The mechanism responsible for a decrease in Aβ42 concentrations is still open to debate.
A recent study found a correlation between lowered CSF Aβ42 levels and the decreased
brain volumes and enlarged ventricles found in AD patients (Wahlund and Blennow,
2003), indicating a possible dilution effect and/or decreased production of Aβ42. It is
more likely that the brain acts as a sink and increased deposition of Αβ42 into plaques
reduces the concentration of Aβ42 remaining to diffuse into the blood.
The use of phosphorylated-tau protein (p-tau) in the CSF as a diagnostic marker
for AD has proven to be far more accurate than Aβ42. P-tau is consistently seen in high
levels in the CSF of AD patients, and is far more specific than Aβ42 or total tau levels for
differentiating AD from other relevant diseases that may cause dementia. It is also useful
for differentiating between geriatric depression and AD, even when there is significant
overlap of clinical symptoms (Buerger et al., 2003). Unfortunately, the sampling
technique used to collect CSF is highly invasive and this limits the application of
both Αβ42 and p-tau as CSF biomarkers in some circumstances. When applicable and in
conjunction with a thorough neurological evaluation and imaging techniques, the use of
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these biological markers is very powerful in increasing the accuracy of AD diagnosis
however.
Some of the more powerful diagnostic markers for AD involve imaging the
medial temporal lobe and monitoring any alterations in particular brain areas. Repeated
MRI studies reveal significant atrophy in this region, specifically in the volumes of the
hippocampus and entorhinal cortex, in early to late stage AD patients (Jack et al., 1997,
Xu et al., 2000). MRI has also been found important in identifying the early conversion
of MCI patients to mild AD patients (DeToledo-Morrell et al., 2004), a potentially
instrumental finding in diagnosing early AD patients at a period where current and future
treatments can exert their most dramatic effects.
An additional tool in the arsenal of AD diagnostics is PET imaging. PET scans
traditionally utilize functional imaging to detect changes in brain metabolism by using a
radioactively labeled isotope that reveals areas of glucose metabolism. This type of PET
scan unfortunately is only useful in detecting changes in the medial temporal lobe in
more advanced AD cases (Ishii et al., 1998), yet this type of imaging is useful in studying
physiological aspects of AD. Recently a radioactive ligand was developed that binds to
Aβ plaques and allows imaging of areas of the brain with large numbers of neuritic
plaques (Klunk et al., 2004). This new technique opens the door for easier evaluation of
anti-amyloid therapies and as another tool in increasing the accuracy of AD diagnosis.
Currently, radioligands for PET imaging of NFT’s remain to be developed yet research
into this area is underway (Mathis et al., 2004).
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Risk Factors for Alzheimer’s Disease
The initial onset and later progression of AD is moderated by the presence or
absence of various risk factors. The most profound and unavoidable risk factor for AD is
aging, yet not all of the elderly will develop AD. Another important risk factor for both
late-onset and familial AD is inheritable, the ApoE4 allele (mentioned earlier as a marker
used in genetic screening). The ApoE4 allele has a gene dose affect: with two copies of
the allele conferring greater risk than possession of one copy of ApoE4 (Veurink et al.,
2003). Inheritance of this allele enhances susceptibility for sporadic AD and also
decreases the age of onset of the disease. ApoE is involved in cholesterol transport and
cholesterol is linked to amyloid deposition and deposition. Therefore, the propensity for
AD due to possession of ApoE4 is believed to be as a result in a deficiency in amyloid
clearance and subsequent increased deposition of beta-amyloid in plaques (Selkoe, 2001).
It is also not surprising that high blood cholesterol (LDL) is also a risk factor for AD.
The neuronal cell losses characteristically seen in AD patients are typically
associated with markers for oxidative stress caused by the body’s inflammatory response
to neuritic plaques and NFTs. A diet poor in antioxidants, such as Vitamin E or others
found in vegetables and fruit, lowers the body’s ability to respond and protect itself from
oxidative stress. Low dietary uptake of antioxidants exacerbates neuronal oxidative
damage and increases the risk for developing AD (Polidori, 2004). High blood levels of
homocysteine are also associated with an increased risk of AD, but it may be as a result
of a folic acid deficiency (Quadri et al., 2004).
Unlike the associated risks for AD mentioned thus far, an environmentally
enriched lifestyle provides protection against AD and decreases the risk of developing
11

dementia with increasing age (Fratiglioni et al., 2004). Such an environment includes
exposure to intellectually stimulating activities, as well as profound social and physical
activities that are usually absent from most nursing homes. The cognitive benefit from
these activities are believed to share the same pathway and all seem to reduce stress,
increase both cognitive reserve and blood flow to the brain (Fratiglioni et al., 2004).
Treatments for AD
Current treatments for AD are based on treating the symptoms rather than the
disease itself. The commonly prescribed acetylcholinesterase inhibitors (donepezil,
rivastigmine, and reminyl) have some efficacy in slowing down the inevitable onset of
neuropsychiatric symptoms in patients with mild to moderate AD (Holmes et al., 2004).
These drugs compensate for the decline in memory due to the deficits in the acetylcholine
neuronal network in the medial temporal lobe. They increase synaptic concentrations of
acetylcholine by blocking the enzyme acetylcholinesterase, which is responsible for
breaking down the neurotransmitter acetylcholine. This increases the efficiency of
remaining cholinergic neurons that have yet to be disrupted from AD progression. As AD
advances these drugs no longer have an affect in preserving memory however. The
acetylcholinesterase inhibitors have a relatively short window of effectiveness, typically
between 1-2 years.
The only other FDA approved drug for treating AD symptoms, Memantine, was
only recently approved for treating moderate to severe AD patients. Memantine is a nonspecific NMDA receptor antagonist that reduces glutamingeric-caused excitoxicity that
may be present in the pathogenesis of AD. Used in conjunction with donepezil,
memantine has been shown to make significant improvements in cognitive function and
12

daily activities in even severe AD patients (Tariot et al., 2004), but like the
acetylcholinesterase inhibitors memantine has a relatively limited duration of
effectiveness.

II. Animal Models of AD
The complex etiology of Alzheimer’s disease requires a practical model that
closely resembles the ontogeny of the disease and can provide insight into possible
therapeutic preventions. Human testing is generally out of the question due to moral
implications in testing novel treatments, so researchers turned to animal models. In
particular, the mouse lines PDAPP, APPsw, and APP/PS1 have been genetically altered to
replicate behavioral and pathological aspects of AD. These mice are manipulated by
randomly inserting a wild-type or mutant AD transgene into the genome of a fertilized
mouse egg. Utilizing a strong promoter that overexpresses the gene in brain-specific
areas, these transgenic mice enable the impact of the gene of interest to be evaluated. The
short life span of mice (1 to 2 years), while beneficial for research, requires that the
promoter overexpress the transgene of interest so the same symptoms that may take
decades to occur in humans will develop in mice (Seabrook and Rosahl, 1999).
Numerous mouse lines have been developed, each with their own assets and drawbacks
in replicating the disease in humans.
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PDAPP Model
Pathology. The PDAPP mouse model incorporates a platelet-derived growth
factor (PDGF)-β promoter in neurons in the brain to drive overexpression of a human
APP minigene associated with the London type mutation (APP717VH F) found in some
familial AD cases. When compared to wild type littermates, this genomic alteration
results in a well characterized, age-dependent neuropathology exhibiting extracellular
levels of Αβ and amyloid deposits similar to that found in AD. Diffuse and mature Aβ
deposits are seen in the hippocampus, corpus callosum, and cingulate cortex as early as 34 months old in PDAPP mice (Dodart et al., 2000). Plaque density increases with age in
these regions and by 6-10 months numerous plaques are seen (Games et al., 1995;
Irizarry et al., 1997). In aged PDAPP mice, increasing plaque burden is associated with
the neuritic dystrophy, cytoskeletal alterations, synaptic degeneration, and gliosis that are
also found in AD patients (Schenk et al., 1997; Larson et al., 1999). PDAPP mice do not
exhibit any neurofibrillary tangles (Masliah et al., 1996) and do not develop the
characteristic neuronal loss associated with AD however. These mice do show marked
hippocampal atrophy by 3 months but this is possibly due to developmental
abnormalities, independent of increased Aβ deposition (Dodart et al., 2000).
Behavior. Important correlations have been made between the pathological
consequences of progressively overexpressing this mutant hAPP gene in PDAPP mice
and the behavioral results that ensue. These mice can be behaviorally tested at various
time points to link cognitive deficits to disruptions in specific brain areas due to
increasing amyloid plaque burden. Initial testing found PDAPP mice develop an agedependent decline in object recognition that the authors linked to the increased levels of
14

Aβ plaques in cortical structures in mice older than 6 months (Dodart et al., 1999). The
same study found deficits in spatial memory in 3, 6, and 9-10 month old PDAPP mice
using an 8-arm radial maze. Deficits in spatial memory at the early 3 month time point
suggest an age independent decline because this is well before significant amyloid
deposition has occurred. In a later paper, the authors attributed this decline in spatial
memory to the overexpression of human APP and subsequent abnormal hippocampal
formation during development rather than increased amyloid deposition (Dodart et al.,
2000). A different study using a novel water maze task revealed an age-related decline in
working spatial memory. These PDAPP mice were found cognitively intact at 6-9
months, but were impaired at 13-15 months and progressively worsened by 18-21 months
(Chen et al., 2000). These authors found this age-dependent decline did correlate with
increased β-amyloid plaques and linked it to interruption of synaptic transmission by βamyloid burden.
Further support for an age-related decline in spatial memory in the PDAPP mouse
line came from a recent study in 2004. This study utilized a PDAPP mouse model that
does not exhibit abnormal hippocampal atrophy during development. Using a full 6 week
battery that examines sensorimotor skills and cognition, Nilsson et al. (2004) found no
differences between 2 month old PDAPP mice and the non-transgenic controls. Another
group of PDAPP mice were tested at 16 months of age and these animals were impaired
in Morris water maze and in overall radial arm water maze performance (RAWM)
(Nilsson et al., 2004). Further statistical analysis of 15-16 month old PDAPP mice found
a significant correlation between deficits in Morris water maze, platform recognition, and
RAWM performance with the deposition of Aβ in the hippocampus and cerebral cortex
15

(Leighty et al., 2004). Such correlations provide evidence that the PDAPP mouse line
develops impaired working memory because of accruing levels of Aβ.
APPsw and APP23 Models
Pathology. The APPsw and APP23 mouse models for AD both incorporate a
human APP gene with the ‘Swedish’ double mutation (K670N/M671L). These mutations
enhance cleavage of APP by β- secretase which favors Aβ42 production. These APPsw
and APP23 models differ however because each one utilizes a different promoter that
overexpresses APP by varying degrees. This difference leads to important distinctions
between the two models in both pathology and behavior.
Initially described by Hsaio et al. (1996), the APPsw mouse line uses a hamster
prion protein promoter limited to neurons in that brain that drives five to sixfold higher
expression of a human APP695 insert when compared to expression of the endogenous
mouse APP gene. The consequences of overexpressing this insert leads to abnormal
changes in the pathology of these mice. Given the nature of the mutations in the insert, it
is not surprising that APPsw mice show increasing levels of total Aβ in the brain.
Specifically, Hsiao et al. (1996) found that the concentration of Aβ40 was 5-times higher
and the concentration of Aβ42 was 14-times higher when comparing APPsw mice between
2-8 months and 11-13 months of age. Rare plaques of insoluble Aβ begin appearing in
small quantities as early as 6-7 months in the hippocampus and entorhinal cortex, with
diffuse and compact plaques increasing to significant numbers by 12 months of age in the
hippocampus and cortex of the brain (Hsiao et al., 1996; Kawarabayashi et al., 2001)
eventually resembling similar levels found in AD patients.
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Importantly, amyloid plaques in the CA1 area of the hippocampus of 16-month
old APPsw mice were found in association with gliosis and neuritic dystrophy (Irizarry et
al., 1997). Other studies have also found activated microglia in response to amyloid
plaques in aged APPsw mice (Frautschy et al., 1998; Benzing et al., 1999). Another study
found an accumulation of prostaglandin E2 (PGE2) and tumor necrosis factor α (TNFα),
both mediators of inflammation from gliosis, in APPsw mice older than 10 months of age
(Quadros et al., 2003). A further study using 21-25 month old APPsw identified areas of
oxidative damage in association with amyloid plaques, likely because of the release of
free radicals during the inflammatory process (Pappolla et al., 1998). The presence of
these inflammatory proteins and Aβ-induced oxidative damage makes this mouse line an
attractive model for testing therapeutics that target the inflammatory cascade seen in AD.
Although the APPsw mouse line replicates several aspects of AD, namely
amyloidosis, vascular angiopathy, free radical formation, and inflammatory mediators in
association with amyloid plaques, it is an incomplete model of AD because these mice
fail to develop neurofibrillary tangles and no global neuronal or synaptic losses have been
reported. Even in aged APPsw mice, where extensive plaque formation is associated with
inflammatory mediators and pro-oxidant activity, neuronal populations remain relatively
consistent with neuronal numbers in non-transgenic controls in areas of the brain such as
the hippocampus, where large numbers of neurons atrophy during the progression of AD
in humans (Irizarry et al., 1997). With no clear abnormalities in the brain structures
associated with learning and memory in these mice, some researchers have suggested that
the increasing soluble levels of Aβ are to blame for the increasing behavioral
impairments that APPsw mice exhibit as they grow older. In fact, one study found severe
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impairment in in vitro and in vivo long-term potentiation (LTP) in neurons of APPsw
mouse hippocampus that correlate with cognitive impairment and rising levels of both
soluble and insoluble Aβ (Chapman et al., 1999).
The other mouse model that incorporates the ‘Swedish’ double mutation, the
APP23 transgenic mouse, employs a murine Thy-1 promoter element to overexpress a
mutant APP751 gene in neurons in the brain. These mice have a seven fold higher
expression of the mutant APP insert than normal mouse APP (Dodart et al., 2002).
APP23 mice develop Aβ plaques in the cortex at 6 months, much sooner than APPsw
mice (Sturchler-Pierrat et al., 1997). Aβ plaque numbers increase with age and spread
extensively in this model to the neocortex, hippocampus, white matter, and thalamus.
Associated with these plaques are dystrophic neurons, activated microglial and
astrocytes. These mice also develop congophilic angiopathy, where large deposits of
Aβ40 are found in conjunction with the brain vasculature (Calhoun et al., 1999), a trait
found in some 90% of AD patients (Vinters, 1987). In striking dissimilarity to the APPsw
mouse model, APP23 mice exhibit a 14% loss of CA1 pyramidal neurons in the
hippocampus in 14-18 month old mice, although no losses are seen in the neocortex
(Calhoun et al., 1998). The authors attribute this loss directly to the formation of dense
Aβ plaques. This model also fails to develop neurofibrillary tangles.
APPsw Behavior. An important component of the behavioral characterization of
transgenic mice is an assessment of any sensory or motor deficits that may influence the
performance of the mice in cognitive-based tasks. Accordingly, the APPsw mouse failed
to show any deficits in a visible platform tasks at either 6 or 9 months of age, indicating
that visual acuity is not impaired in these mice (Holcomb et al., 1999). Further
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sensorimotor evaluation, assessed through the use of various agility tasks and a Preyer
reflex test, also failed to detect any significant disturbances (Holcomb et al., 1999;
Holcomb et al., 1998). In a later study, APPsw mice at 3, 9, 14, and 19 months of age
were subjected to a full battery of sensorimotor tasks. The authors concluded that
younger APPsw mice are not impaired in motor function overall, and older transgenic
mice show impairment similar to non-transgenic controls (King et al., 2002). Recently,
Arendash et al., (2004) reported that 6 month old APPsw are impaired in a balance beam
task, but perform normally in the elevated maze task for anxiety and other sensorimotor
tasks, such as string agility. Additionally, Leighty et al. (2004) found no correlation
between the balance beam task, a measure of sensorimotor skills, and cognitive
performance. The lack of any sensory or motor abnormalities in APPsw mice, or
significant correlation with cognitive performance, validates linking any performance
issues in cognitive-based tasks to disruptions in memory, not to the physical attributes of
the mice.
The Y-maze alternation task has elucidated deficits in mnemonic processing in
the APPsw mouse, but inconsistently so. Hsiao et al. (1996) first found 3 month old APPsw
mice performed similar to controls, yet 9 month old Tg+ mice showed significant
impairment in spontaneous alternation in this task. King et al. (2002) found APPsw mice
aged 3, 9, 14, and 19 months had an “overall” reduced alternation in the Y-maze task
when all age groups were analyzed collectively. In a later study, Arendash et al. (2004)
found APPsw mice were impaired overall in spontaneous alternations at 5 and 8.5 month
time points collectively. On the other hand, Holcomb et al. (1999) reported APPsw mice
were impaired in alternation behavior at 3 months yet were unimpaired at 9 months of
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age. This task is likely not as sensitive as some of the other cognitive-based tasks because
Y-maze impairment remains inconsistent in this mouse model, although differences in
methodologies and genetic backgrounds may play a role in these discrepancies.
Not surprisingly, 15-17 month old APPsw mice also showed significant T-maze
alternation impairment (Chapman et al., 1999). The authors correlated the poorer T-maze
impairment to their in vivo findings of impaired long-term potentiation in both the CA1
and dentate gyrus regions of the hippocampus from the same mice and suggest that rising
Aβ levels in these aged mice acts directly to infer synaptic deficiencies evident in
reduced LTP. Unfortunately at this late age, the authors could not discriminate between
the effects of soluble or insoluble Aβ, although the authors hint diffusible forms of Aβ
are most likely responsible. This group also showed the APPsw mouse model lacks
deficits in sensorimotor attributes, but only used an open field task to claim this.
Initial cognitive testing of APPsw mice using the Morris water maze revealed no
differences in learning and memory in spatial reference tasks between non-transgenic and
transgenic mice at 3 months of age (Hsiao et al., 1996). At a later age in this study
however, 9 month old APPsw were found impaired in their escape latency in the same
task and also spent less time in the platform’s quadrant in the probe trial, indicating these
mice did not learn the location of the platform. Recently in 2004, however, Arendash et
al. found impaired acquisition and retention performance in the Morris water maze as
early as 5.5 months of age, suggesting the initial appearance of small Aβ oligomers are
responsible for impairment of both reference learning and memory. A previous study
done by King and Arendash (2002) reported their mice were unimpaired in Morris water
maze even up to 19 months of age. These contrasting results from the same lab were
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suggested to be caused by the different background strains of the mice used in these
studies or by changes in their genetic backgrounds caused by multiple generations of
inbreeding. These differences enabled the effects of the transgene to become more
evident in the later study. Further evidence for the role of cognitive disturbances by small
Aβ oligomers came from a study that reported impaired reference memory in the Morris
water maze task at 6 months of age in APPsw mice (Westerman et al., 2002). Although
one study using the Morris water maze failed to replicate cognitive impairment in 6 or 9
month old APPsw mice, this is likely because of differences in testing paradigms and the
genetic backgrounds that exist between mouse colonies in different labs (Holcomb et al.,
1999). In summary, the consensus of the behavioral studies thus far indicate Morris water
maze impairment in APPsw mice begins around 6 months of age.
Using a circular platform task adopted from rat behavioral studies, King et al.
(2002) found 3, 9, 14, and 19 month old APPsw mice perform comparably to nontransgenic age-matched controls, with both groups showing a learning effect that reduced
the number of errors made over the 7 day testing period. Arendash et al. (2004) reported
no differences between 6 month old APPsw mice and non-transgenics in circular platform
performance as well. Testing by Pompl et al. (1999) revealed impairment in 7 month old
APPsw mice during a reversal learning phase of the circular platform task however. APPsw
mice learned the location of the escape hole in relation to various cues as well as nontransgenic mice; however, when the escape hole was moved, transgenic mice showed
increased errors and escape latency that failed to improve. This is a different variation of
the task however, and the literature is consistent in reporting a lack of impairment of
APPsw mice in the standard circular platform task at any age.
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Additionally, APPsw mice repeatedly show poor performance in other cognitive
tasks. Hsiao et al. (1996) reported impaired platform recognition latency in 9-10 month
old APPsw mice that coincided with increases in soluble Aβ. King et al. (2002) also
showed APPsw mice at 9 months of age were significantly slower in locating a visible
platform, and both of theses studies performed the platform recognition task after
conducting the Morris water maze task. Recently, a similar behavior paradigm using the
platform recognition task identified impairment even earlier in 6 month old APPsw mice
(Arendash et al., 2004). In contrast, Westerman et al. (2002) found unimpaired platform
recognition performance throughout the 2 year life span of the mice, but this test was
performed before Morris water maze testing. Impaired escape latency for APPsw mice in
the platform recognition task thus has been suggested to reflect difficulties in switching
between the spatial (cued) strategy used in Morris water maze to a search/recognition
strategy that ignores the previously learned extra-maze spatial cues. This explains why
APPsw mice are impaired in the platform recognition task after they have already learned
the platform location in the Morris water maze task, but have not been impaired in the
platform recognition task if it is done prior (Arendash et al., 2004, Westerman et al.,
2002).
The radial arm water maze (RAWM) is a sensitive working-memory task used to
evaluate both short term memory and delayed memory recall. The first testing of APPsw
mice in the RAWM task found 15.5 month old mice made significantly more errors in the
trial 5 component of the task when compared to non-transgenic controls, indicating these
mice were deficient in working memory (Morgan et al., 2000). RAWM testing of
younger 6.5-7 month old APPsw mice revealed that these animals made more errors
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overall in both the trial 4 and trial 5 components of the task, further highlighting the
deficits these mice have in working memory (Arendash et al., 2004). The consistent
working memory impairment these mice show in this task by 6.5 months of age indicates
the oligomeric form of Aβ is likely responsible for their cognitive impairment, as these
young mice have yet to develop amyloid plaques.
In summary, APPsw mice do not develop any gross sensorimotor deficits that
would otherwise impair performance in cognitive tasks. These mice consistently develop
significant impairment in reference learning/memory that is apparent in the Morris water
maze as early as 5.5-6.5 months and is likely caused by the increasing amounts of soluble
Aβ oligomers. The difficulties in switching escape strategies are also apparent for 9
month or older APPsw mice in the platform recognition task, which is reflected in their
increased escape latencies. APPsw mice also exhibit working memory impairment in the
RAWM task at 6.5 months of age, as these mice make more errors in the trial 4 and 5
components of the task. Based on these overall behavioral findings, it is reasonable to
expect 8-9 month old APPsw mice will have impaired reference learning/memory,
impaired recognition/identification, and impaired working memory evident in the tasks
discussed thus far.
The APP23 mouse model has undergone behavioral characterization as well. A
behavioral characterization of the APP23 model was done by Kelly et al. (2003) at 3, 18,
and 25 months of age using passive avoidance tasks, platform recognition, and small and
large Morris water maze tasks. Age-related impairments in passive avoidance and in
small pool acquisition were reported, while APP23 mice were found to be impaired at
every time point in the larger Morris water maze during acquisition testing. The authors
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also reported visual deficiencies were not responsible for this impaired spatial learning by
using a platform recognition task in the larger pool. An age-related decline in Morris
water maze and probe trial performance was reported also at the early age of 3 and 6
months, while 2 month old animals were unimpaired when compared to non-transgenic
controls (Van Dam et al., 2003). Further studies have also reported progressive deficits in
acquisition (learning) of the Morris water maze task in both 16 month (Lalonde et al.,
2002) and 2 year old APP23 mice (Dumont et al., 2004). In addition, increased
exploratory behavior was detected in 2 year old APP23 mice through the use of the open
field task, while anxiety was decreased in the open arm (+) maze task (Dumont et al.,
2004). The repetitive results of impaired spatial memory in APP23 mice in the Morris
water maze indicates these animals represent an effective model for behavioral testing in
AD, yet the behavior of these mice in working memory tasks, such as the RAWM, that
examine long term memory remains to be determined.
PSAPP Model
Pathology. The PSAPP, or APPsw/PS-1, mouse model is a combination of two
mutations associated with familial Alzheimer’s disease. The same “Swedish” mutation
used in APPsw mice that enhances β-secretase activity on APP and a PS-1 mutation that
favors the enzymatic cleavage of APP by γ-secretase are both overexpressed in this
model resulting in an exponential increase in Aβ levels with aging, even when compared
to that of transgenic APPsw mice (Holcomb et al., 1998). Studies have shown that PSAPP
mice begin showing Aβ deposits in both the hippocampus and cortex between 3-6
months of age (Takeuchi et al., 2000), with significant numbers present by 9-12 months
of age (Borchelt et al., 1997; Holcomb et al., 1998). Although deposits of Aβ resemble
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those found in AD, compact plaques of fibrillar Aβ have been reported to form before
diffuse plaques in the PSAPP model, whereas this trend is opposite in human AD
(Gordon et al., 2002). Nevertheless, by 12 months of age the compact plaques in PSAPP
mice are surrounded by dystrophic neurites, reactive microglia and GFAP-expressing
astrocytes, indicating that a neuroinflammatory response is present (Gordon et al., 2002).
In depth analysis of the inflammatory response in PSAPP mice found that amyloid
plaques increase continuously with age up the latest age studied, 25 months (Matsuoka et
al., 2001). These authors found cyclooxygenase-2 (an inflammatory response protein) in
conjunction with the astrocytes surrounding amyloid plaques. Complement component 1q
was identified with the microglia associated with amyloid plaques, which indicates
microglia may be attempting to clear amyloid via the complement pathway.
Like the other AD animal models discussed thus far, the PSAPP mouse line also
fails to develop neurofibrillary tangles. Takeuchi et al. (2000) reported a non-significant
loss in cortical and CA1 neurons of the hippocampus in 12 month old PSAPP mice, yet
this study used a low sampling number. A further study of 22 month old PSAPP found a
38.5% reduction in CA1 pyramidal neurons (Sadowski et al., 2004). Deficits in LTP have
also been found as early as 3 months in PSAPP mice, when amyloid plaques and deficits
in short term memory first appear (Trinchese et al., 2004).
PSAPP Behavior.

The first study to examine behavioral aspects of PSAPP mice

found that by 3-4 months these mice had significantly impaired alternation performance
in the Y-maze task, months before the initial deposition of Aβ has been detected
(Holcomb et al., 1998). The same lab found that this deficit in Y-maze performance
persisted with increasing age, as PSAPP mice were also impaired at 6 and 9 months of
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age (Holcomb et al., 1999). This same study also failed to detect any deficits in spatial
working memory at 6 or 9 months of age using the Morris water maze. These results
show that behavioral deficits are likely due to the presence of soluble Αβ. Using a full
behavioral battery, a later study found that PSAPP mice showed no change in
spontaneous Y-maze alternations at either 5-7 or 15-17 months of age (Arendash et al.,
2001). This same study also showed normal Morris water maze performance at 5-7
months of age but an aged-related impairment in this task was found later at 15-17
months. Another study investigating the effects of a lifelong immunization with human
Aβ found unvaccinated PSAPP mice were impaired in both Morris water maze and the
radial arm water maze (RAWM) at 4-6 months and 15-16 months of age (Jensen et al.,
2005). Similar impairments in RAWM at 15.5 months were reported in another study of
PSAPP mice (Morgan et al., 2000). The findings of cognitive impairment at such an early
age in this same colony of mice was attributed by the authors to multiple generations of
crossbreeding that enhances the susceptibility of the mice to the effects of mutant APP
overexpression.
Early PSAPP working-memory deficits at 3-4 months of age in the RAWM and
impaired reference-memory in the Morris water maze at 6-8 months were also reported
by Trinchese et al. (2004). The working-memory impairment was evident in the number
of errors the PSAPP mice made in the RAWM that strongly correlated with Aβ levels
and amyloid burden in these mice. A further correlation was made between RAWM
errors and synaptic deficiencies in LTP at 6-8 months of age. The authors propose this
lends additional support to the idea that increasing Aβ levels and amyloid burden impair
LTP, thus reducing the animals’ performance in tasks based on cognition.
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Limits of Animal Models for Alzheimer’s disease
In addition to the various pathological aspects of AD that fail to materialize in AD
transgenic mice (such as neurofibrillary tangles or global neuronal loss that were
mentioned earlier for each specific model) are differences in mouse and human pathology
that possibly may skew the generalizations made after a potential therapeutic is tested.
Specifically, Aβ plaques in both APP23 (Kuo et al., 2001) and APPsw mice (Kalback et
al., 2002) were found to be soluble in SDS-containing buffers whereas human Αβ
plaques are not, indicating mouse plaques are less dense. This distinction is important
because it is believed to be responsible for the weaker complement response to Αβ
plaques and the resultant weaker inflammatory cascade found in APP23 mice (Schwab et
al., 2004). Knowing that human fibrillar Aβ plaques are neurotoxic from in vitro studies
(Lorenzo et al., 2000), a less compact form of these plaques in the mice may also explain
the lack of neuronal losses in animal models of AD.
Transgenic mice are also incomplete in their behavioral replication of the disease.
Many of the behavioral aspects of early Alzheimer’s disease are difficult to ascertain in
humans even through the use of cognitive tests such as the MMSE that examine various
aspects of memory. Semantic memory, such as word or event recall, is usually the first
apparition signaling Alzheimer’s disease in humans and cannot be assessed in a mouse
animal model. Obviously the language difficulties which surface in moderate AD are also
problematic to examine in mice. Mouse animal models are thus limited to behavioral
measures that examine spatial learning/memory, recognition/identification, exploratory
behavior, sensorimotor skills, and anxiety, which may only give some insight into the
onset of depression, motor skills, or memory impairment of this disease in mice.
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Given these limits in replicating all aspects of Alzheimer’s disease, transgenic
mice still have been paramount in our understanding of the disease and the possibility of
developing therapeutics that lay the foundation for future clinical testing looks promising
through the use of these mice.

III. Caffeine Consumption and Alzheimer’s Disease
There is little doubt that the widespread consumption of caffeine by the global
population makes it an important consideration when evaluating dietary influences on the
etiology of human diseases. Caffeine can be found in popular foods and beverages such
as tea, coffee, cocoa, chocolate, and soft drinks that constitute dietary items consumed
sometimes as a chronic staple of the Western diet. The average caffeine consumption in
the US is equivalent to 1-2 cups of coffee a day, or 168 mg/person/day (Fredholm et al.,
1999). Caffeine may also be found in certain aspirins and other over-the-counter drugs,
although these would not represent a source of long-term caffeine ingestion.
Caffeine’s stimulatory effects on behavior and attention have been known for
some time, but its effects on other aspects of human neurobiology have only recently
begun to be explored. Epidemiological studies indicate that sufficient daily caffeine
intake throughout life may be neuroprotective in both Parkinson’s disease (Ross et al.,
2000) and Alzheimer’s disease (Maia and Mendonca, 2002). Notably, Maia and
Mendonca found that AD patients consumed markedly less caffeine (74 mg/day) during
the twenty years preceding diagnosis of AD when compared to age-matched controls
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(199 mg/day). Daily caffeine intake included any potential sources of caffeine and was
not solely restricted to caffeine ingested from coffee. This information suggests that
chronic caffeine intake during the middle years of life may delay or even prevent
altogether the onset of the behavioral symptoms seen in sporadic Alzheimer’s disease, an
important finding.
The molecular mechanism(s) that grants caffeine’s neuroprotective effects
remains to be clearly elucidated, but many possibilities have been suggested. Once this
mechanism has been identified, caffeine-based therapeutics could become useful in
treating neurodegenerative diseases because of their availability and general lack of longterm side effects.
Pharmacological Profile of Caffeine
Whether taken orally or administered intravenously, the pharmacokinetics of
caffeine are identical in humans and animals (Arnaud, 1993). Likewise, the
gastrointestinal absorption and bioavailability of caffeine reaches 99-100% within 45
minutes of ingestion in both human and animal models (Bonati et al., 1984, Blanchard
and Sawers, 1983a). Peak plasma level of caffeine is reached between 15 and 120
minutes after ingestion in humans, with a half-life that ranges from 2.5 to 4.5 hours in
humans (Arnaud, 1987) and only 0.7 to 1.2 hours in rats and mice (Bonati et al., 1984). It
is also known that the plasma half-life of caffeine remains relatively unchanged in both
young adults and the elderly (Blanchard and Sawers, 1983b). On average, a typical cup of
coffee provides a caffeine dose of 0.4 to 2.5 mg/kg which gives a peak plasma
concentration of caffeine of 1 to 10 µM (Fredholm et al., 1999). This information, once
accounting for weight and metabolic differences between animal models and humans,
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allows for interpolations for dose-dependent effects between caffeine studies in animal
models and humans.
Caffeine’s hydrophobic nature allows for rapid absorption through all biological
membranes, hence its rapid absorption into the bloodstream. This same tendency also
allows caffeine to freely pass through the blood brain barrier (Tanaka et al., 1984), an
obstacle that limits the design and size of many other potential neurotherapeutics. Once
absorbed into the blood stream, caffeine is also broken into its main derivatives by the
liver. Caffeine’s major metabolites in rodents and humans with bioactivity include 1,3dimethylxanthine (theophylline) and 1,7-dimethylxanthine (paraxanthine). Both of these
compounds were found to mimic some of caffeine’s effects in the CNS and which will be
discussed in greater detail later on (Benowitz et al., 1995). Theophylline in particular is
of interest because of its common use as a treatment for asthma and other diseases that
increase bronchial constriction.
Molecular Actions of Caffeine
Caffeine has been used experimentally for some time to study its inhibitory effect
on cyclic nucleotide phosphodiesterase isozymes of the brain and other tissues of the
body (Vernikos-Danellis and Harris, 1968). The caffeine dose needed in order to achieve
this effect, however, is within the millimolar range which far exceeds typical human
plasma levels of caffeine after ingestion. This same range is also required to release
intracellular calcium stores via activation of ryanodine receptors (McPherson et al.,
1991). In addition, caffeine plasma levels in excess of 500 µM, or more than 50 cups of
coffee, are toxic, likely because of caffeine’s blockade of GABAA receptors at this
extreme range (Fredholm et al., 1999). Therefore, it is reasonable to assume that neither
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of these actions of caffeine can be attributed to its neuroprotective effects that are being
investigated. The only other molecular action of caffeine that can be achieved within
physiological doses in the CNS is adenosine receptor antagonism, a mechanism that is
shared by both theophylline and paraxanthine. In fact, theophylline’s affinity for
adenosine receptor antagonism is three to five times higher than caffeine (Fredholm et al.,
1999). Theophylline has also been shown to enhance hippocampal LTP, yet the dose
needed for this effect is in the 100 to 1000 µM range which is beyond that of typical
caffeine consumption (Tanaka et al., 1990).
Adenosine. As the main constituent of ATP, adenosine is present both
intracellularly and extracellularly throughout the body. Although adenosine is an
important modulator of neurotransmission, it is not considered a classical
neurotransmitter because it is neither stored in vesicles nor dependent on Ca+ for release
(Fisone et al., 2004). Instead, adenosine is transported between the cytoplasm and
extracellular space through equilibrative nucleoside transporters. The direction of this
transport is dependent on the adenosine concentration gradient in both sides of the
membrane (Gu et al., 1995), which under normal conditions facilitates the intra-cellular
transport of extracellular adenosine as adenosine is incorporated into AMP intracellularly
via the enzyme adenosine kinase. During times of physiological stress, such as ischemia
or hypoxia, intracellular levels of adenosine rise due to hydrolysis of ATP which
subsequently fuels an increase in the extracellular concentration of adenosine (WallmanJohansson and Fredholm, 1994). Aside from adenosine efflux from the cytoplasm, a
second minor source of adenosine exists in the extracellular space that involves the

31

conversion of released adenine nucleotides into adenosine by several enzymes
(Zimmerman and Braun, 1999).
Rising extracellular levels of adenosine are thus viewed as a protective response
from metabolic injury and various therapeutics have been proposed recently to
specifically raise extracellular adenosine levels. In particular, the drug propentofylline
has been forwarded as a potential treatment for Alzheimer’s disease, and it showed
promising results in a clinical study (Kittner et al., 1997). One role of this drug is
blockade of the equilibrative adenosine transporters, which leads to an increase in
extracellular adenosine levels because of the conversion of adenine nucleotides into
adenosine mentioned earlier. The elevation of extracellular adenosine levels
downregulates activated glial cells and leads to the restoration of altered calcium
homeostasis (Ringheim, 2000). Likewise, the drug dipyridamole blocks adenosine uptake
and inhibits the enzyme adenosine deaminase that breaks down adenosine, thus leading to
increased extracellular concentrations and has been shown to block the enhanced
vasoconstriction induced by soluble Aβ by increasing cGMP activity (Paris et al., 1999).
Adenosine itself is also administered commonly by paramedics as a treatment to slow
atrial tachycardia by increasing conduction time through the AV node. Finally, it has also
been found that long-term ingestion of caffeine in rats leads to significantly increased
levels of adenosine in blood plasma in a dose-dependent manner through an unknown
mechanism (Conlay et al., 1997). Although adenosine does not cross the blood brain
barrier, it can be assumed a rise in brain adenosine levels should accompany rises in
plasma adenosine levels because caffeine can enter the brain from plasma and exert
similar effects on adenosine receptors there as well.
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Adenosine Receptors. Currently, four G-protein-coupled receptor (GPCR)
subtypes have been identified to have adenosine affinity. These subtypes, named A1, A2A,
A2B, and A3, are expressed throughout the brain in particular and in both the central and
peripheral nervous system (Fredholm et al., 1994); they are collectively referred to as the
P1 (adenosine selective) receptors. The high affinity receptors A1 and A2A are typically of
interest because they are most likely responsible for the neuromodulatory effects of
adenosine at physiological levels, while the lower affinity A2B receptors have been
relatively ignored because they are most likely only activated when adenosine levels are
increased (Fredholm et al., 1999; Fisone et al., 2004). The low affinity A3 receptors are
sparsely distributed in humans and are little affected by caffeine or its metabolites in rats
(Fredholm et al., 1999). Although A2B and A3 receptors cannot be completely excluded
from having a neuroprotective effect in relation to caffeine, this is simply because
evidence that might support such a role is lacking so these receptors are not included in
this thesis. Refer to Figure 1 at the end of this section for an overview of caffeinemediated effects by adenosine receptor antagonism.
The A1 type adenosine receptors have high affinity for both caffeine and
adenosine. These receptors are widely distributed in the brain, with higher expression in
the cerebral cortex, cerebellum, hippocampus, and in the dorsal horn of the spinal cord
(Ribeiro et al., 2003), while lower expression levels of this receptor are also found in the
basal ganglia (Rivkees et al., 1995). These receptors (along with the A3 receptors)
activate inhibitory G-proteins (both Gi and Go) which may lead to the inhibition of
adenylyl cyclase, closure of Ca2+ channels (MacDonald et al., 1986), and activation of
K+ channels (Trussel and Jackson, 1985). Inhibition of adenylyl cyclase ultimately leads
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to decreased production of cAMP, thus activation of these receptors is generally thought
to provide an inhibitory effect on secondary messenger systems while stabilizing the
cellular membrane by blocking Ca2+ influx.
The A1 receptor is present on the membranes of neurons, microglia, and
astrocytes (Ongini and Schubert, 1998). The majority of neuronal adenosine A1 receptors
are located on presynaptic nerve terminals where they provide inhibition of
neurotransmitter release after activation by adenosine (Fisone et al., 2004), although
some post synaptic A1 receptors may also exert an inhibitory effect (Ribeiro et al., 2003).
Most importantly, activation of A1 receptors has been shown to limit neuronal release of
the excitatory amino acid glutamate (Flagmeyer et al., 1997) and decreases in
acetylcholine release have also been reported (Brown et al., 1990). Activation of A1
receptors in the striatum was also linked to inhibition of the D1 receptor-mediated
increase in adenylyl-cyclase activation (Abbracchio et al., 1987), giving an explanation
for the reports of decreases of striatal extracellular dopamine levels following A1 receptor
activation (Okada et al., 1996). Caffeine administration would disinhibit these neurons,
leading to an increase in neurotransmitter release (see Figure 1).
The inhibitory effect of adenosine A1 receptor activation on glutamate release and
Ca2+ influx likely is responsible for the neuroprotection (particularly in hippocampal
regions) seen when animal models of cerebral ischemia are administered A1 selective
adenosine receptor agonists (Rudolphi et al., 1989). The stabilization of Ca2+ homeostasis
after A1 receptor activation raises the depolarization threshold needed to remove the Mg2+
blockade in NMDA receptors (present in large numbers in hippocampal neurons) leading
to a reduced risk of excitotoxicity (Ongini and Schubert, 1998). Treatment with an A1
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selective adenosine receptor antagonist on the other hand, is shown to exacerbate damage
in the hippocampus during ischemia because of the increased exposure to excitotoxicity
(Rudolphi et al., 1997).
The A2A type adenosine receptors also have high affinity for caffeine and are
activated by the nanomolar concentrations of adenosine present during normal
physiological conditions in the brain (Fisone et al., 2004). These receptors are highly
expressed in the basal ganglia, particularly in the striatum, and the olfactory bulb, while
much lower levels of this receptor are found in the hippocampus and cortex (Sebastiao
and Ribeiro, 1996). The A2A receptors activate stimulatory G-proteins (Gs in the
periphery and Golf in the striatum) which in turn activate adenylyl cyclase (Herve et al.,
2001) and may also activate voltage-sensitive Ca2+ -channels in certain cells (Fredholm et
al., 1999). It has been shown in some hippocampal neurons that A2A receptor activation
upregulates Ca2+ uptake via class A calcium channels, through the activation of adenylyl
cyclase signaling (Goncalves et al., 1997). Notably, A2A adenosine receptors sometimes
are located with A1 receptors on the same cells, indicating these different receptor types
may have opposing roles when on the same cell. Indeed, in the striatum (a brain area
where A2A receptors are high and A1 receptors are low) activation of the A2A receptor
leads to a desensitization of the A1 receptor (Dixon et al., 1997). The end result of
adenosine receptor activation thus may depend on the densities of each receptor type in
that particular brain area.
A2A receptors are located on both neurons and microglia, but not on astrocytes
(Fiebach et al., 1996). A2A receptors are also present on coronary arterial walls and upon
activation cause vasodilation (Linden, 2001). In addition, A2A receptors are also located
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in the periphery on bone-marrow derived cells; such as neutrophils, monocytes,
macrophages, platelets, and mast cells, where in vitro activation of these receptors has
been shown to reduce the release of reactive oxygen species and the pro-inflammatory
cytokine TNF-α (Sullivan, 2003). An in vivo study confirmed that genetic inactivation of
A2A receptors in the periphery results in the loss of a negative feedback mechanism that
would otherwise limit a systemic inflammatory response and reduce tissue damage (Ohta
and Sitkovsky, 2001). This suggests that A2A receptor activation potentially might reduce
the pro-inflammatory component of the amyloid cascade in the brains of Alzheimer’s
afflicted patients. Expression of A2A receptor mRNA on glial cells in the brain is limited
however (Schiffman et al., 1991), thus their role in any A2A-modulated actions is unlikely
to be significant. Therefore, blockade of glial A2A receptors by caffeine would also be
limited so it should not have a noticeable effect on inflammation in Alzheimer’s disease
(see Figure 1).
Activation of A2A receptors by selective A2A receptor agonists has shown
significant increases in extracellular glutamate levels in the striatum (Popoli et al., 1995)
and cerebral cortex (O’Regan et al., 1992), providing evidence that activation of striatal
A2A adenosine receptors gives a detrimental effect during times of ischemia and/or
excitotoxicity in direct contrast with A1 receptor-mediated protection. Accordingly, A2A
receptor blockade by selective A2A adenosine receptor antagonists has been found to
reduce neuronal striatal damage induced by the excitotoxin quinolic acid (Popoli et al.,
2002) and A2A receptor KO mice have been reported to be protected against MPTPinduced neuronal damage in the striatum (Chen et al., 2001). With this information in
mind, any neuroprotective effects of A2A antagonists against Alzheimer’s are likely due
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to vasodilatation in the periphery, rather than in the brain itself because excitotoxic
damage is not indicated in striatal areas in patients with this particular disease.
Particularly in Parkinson’s research, neuronal A2A receptors have received intense
interest because of their roles in dopaminergic transmission in the dopamine rich areas of
the striatum. The majority of striatal A2A expression is found in association with the
inhibitory dopamine activated D2 receptors on the GABAergic medium-sized neurons of
the indirect pathway that project from the striatum to the globus pallidus and subthalamic
nucleus (Ferre et al., 1997). Under normal conditions, dopamine is the major modulator
of this pathway, with A2A receptors playing an opposing role to activation of the
inhibitory D2 receptors. When dopamine levels diminish in Parkinson’s disease, this
GABAergic/globus pallidus/subthalamic nucleus pathway is overactive, contributing to
the motor abnormalities present in this disease. Thus A2A specific antagonists have been
forwarded to potentially correct this imbalance, in addition to their neuroprotective effect
mentioned earlier. While this information is important for potential therapeutics against
the degeneration of the dopaminergic system seen in Parkinson’s disease, it is unlikely to
have much bearing in Alzheimer’s disease.
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Figure 1. Receptormediated effects of
caffeine intake

Caffeine Intake

A1 Receptor Antagonism

A2A Receptor Antagonism

↑ cAMP
↑ Glutamate release
↑ Acetylcholine release
↑ Ca2+ Influx

Hippocampus/Cortex

Unknown

↑ Dopamine release

Striatum

↓ cAMP
↓ Glutamate release
↓ GABA
↑ Dopamine release

Unknown

Global CNS

↑ Glial Activation
↑ Vasoconstriction

Immediate Effects of Caffeine Intake
Physiological Changes. The initial absorption of caffeine into the bloodstream
creates widespread changes throughout the CNS. Acute doses of caffeine lead to
increases in cerebral energy metabolism in areas of the brain responsible for motor
activity and the sleep cycle, and this response is not abolished by any appearance of
tolerance (Fredholm et al., 1999). Surprisingly, this increase in cerebral metabolism is
also accompanied by a decrease in cerebral blood flow due to the cerebral
vasoconstriction induced by caffeine seen during rest (Higashi et al., 2004). Caffeine’s
effect on alertness is positive however, so it is likely that any increases in metabolism
with reduced blood flow are met with increased glucose utilization. Interestingly, 1-5
mg/kg doses of caffeine in rats leads to widespread increases in glucose utilization
throughout the brain, including areas of the cortex, hippocampus, and central components
of the nigrostriatal dopaminergic system (Nehlig and Boyet, 2000). A caffeine-induced
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increase in metabolism coupled with decreased blood flow could potentially lead to
increased levels of extracellular adenosine in an ischemic-like response.
In the absence of caffeine, adenosine levels increase during prolonged
wakefulness which suppresses cortical activity by activating the inhibitory A1 receptors
on mesopontine cholinergic neurons (Rainnie et al., 1994). The increase in cortical
activity following caffeine intake evident in the electroencephalogram (EEG) as
decreases in delta and theta waves and an increase in alpha and beta waves (Patat et al.,
2000) is thus linked to caffeine’s antagonism of A1 receptors on these particular neurons.
Caffeine also decreases GABA release in the globus pallidus, leading to increased
activity in this region as well (Fredholm et al., 1999). Furthermore, a microdialysis study
with rats found that caffeine administration dose-dependently raised dopamine and
acetylcholine concentrations in the prefrontal cortex (Acquas et al., 2002). The authors
also reported the increases in dopamine concentrations were lost after tolerance
developed to chronic caffeine treatment, while caffeine’s affects on acetylcholine were
not. This information lends support to the reported positive affect of caffeine on alertness
that is not lost in chronic caffeine users.
Behavioral Effect. Although acute use of lower doses of caffeine is known to
promote locomotor effects in caffeine intolerant rodents, the exact mechanism for this
action remains to be clearly pinpointed to one receptor. Acute doses of caffeine given in
mice in particular are reported to decrease exploratory behavior in the open field (Meyer
and Caston, 2004) and increase anxiety in the plus-maze task (Silva and Frussa-Filho,
2000). Given that A2A receptors are found in particular abundance in the striatum (an area
of the brain profoundly involved in locomotion) it has generally been assumed that
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blockade of A2A receptors following caffeine administration is mainly responsible for the
changes in locomotor activity (see Table 1). Concordantly, it is not surprising that A2A
receptor KO mice are resistant to the stimulatory effects of caffeine (Halldner et al.,
2004).
Caffeine also is reported both anecdotally and experimentally to provide an
immediate positive effect on learning and memory. It is interesting to note that a study
found an acute dose of caffeine administered to caffeine-naïve rats after training in the
Morris water maze improved their reference memory in the probe trial at doses of 0.3-10
mg/kg, whereas a higher does of 30 mg/kg had no effect on performance (Angelucci et
al., 2002). Acute caffeine doses of 0.1-0.3 mg/kg also were also found to reverse memory
disruption in the two-way active avoidance task induced by MPTP injections in rats
(Gevaerd et al., 2001). Additional studies found that administration of an A1 specific
receptor antagonist MDL102503 to rats reverses scopolamine-induced memory
impairment in the water maze. In addition, another A1 specific receptor antagonist
(KFM19) also improved performance in other cognitive based tasks, such as the Y-maze
(Jacobson et al., 1996). Castellano (1976) also found a caffeine dose of 1 mg/kg to mice
improved the learning and consolidation processes in a Y water maze task.
Although these studies give evidence for a potential positive effect on memory by an
acute dose of caffeine in rodents, they don’t provide much insight into the effect a longterm treatment of caffeine might have on memory and learning in rodents. Furthermore, it
is also difficult to tell if improved performance in these cognitive tasks following acute
doses of caffeine is simply related to increased alertness in these mice and not an increase
in memory or learning. For instance, caffeine doses of 2.5 and 5 mg/kg had no effect on
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avoidance learning of mice in the shuttle-box avoidance test, while caffeine doses of 10
mg/kg actually impaired their performance (Sansone et al., 1994). Similar results were
found by Izquierdo et al (1979), who found mice administered 29.9 mg/kg of caffeine
were significantly impaired in their memory retention in the passive avoidance task. It is
likely alertness is less of a component in mouse performance in the avoidance tasks,
because these tasks utilize a conditioned response rather than the reliance on spatial cues
for orientation in the Morris water maze. Lastly, a study using wild type rats found that
acute doses of caffeine improve tracking performance, indicating improved alertness
(Evenden et al., 1993) (see Table 1 for a summary of these results).
Controlled human studies have produced mixed results. James (1998) reported no
effects of caffeine on performance were seen when administered on either an acute or
chronic basis. This study did find participants were more alert and less tired following
acute intake of caffeine, but felt less alert following chronic exposure to it. A study that
stratified the dose-dependent effects of caffeine found caffeine administered at a lower
dose (250 mg) produced pleasant subjective feelings and positive effects on performance
whereas a higher dose (500 mg) produced unpleasant subjective feelings and decreased
performance (Kaplan et al., 1997). Differences in performance were also reported
between studies using low dosages of caffeine. A low dose of caffeine (100mg) failed to
have an effect on short or long-term memory retrieval in middle to elderly men and
women (Schmitt et al., 2003). A study utilizing a CANTAB battery found 60 mg of
caffeine sped up reaction times in pattern recognition, delayed match to sample, and
match to sample visual searches (Durlach et al., 1998). Both of these studies are similar
however because they included habitual caffeine users forced to abstain from caffeine for
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the study purposes. This is significant because another study reported the caffeineinduced increase in a sustained attention task was abolished when the moderate caffeine
users were tested after no longer being deprived of caffeine (Yeomans et al., 2002). The
authors go on to theorize that caffeine’s beneficial affect on memory is mainly due to
withdrawal reversal, a likely suggestion supported by information gleamed from animal
studies dealing with acute or chronic doses of caffeine.
Table 1. Immediate Effects
of Moderate Caffeine Intake
Physiological

Receptor Action

Cerebral Vasoconstriction

Global vasculature A2A antagonism

Increased glucose utilization

Unknown

Increased cortical EEG activity

Mesopontine Cholinergic A1 antagonism

Neurotransmitter Disinhibition

A1 antagonism

General Behavior

(Humans and Rodents)

Increased alertness

Mesopontine Cholinergic A1 antagonism

Increased anxiety

Striatal A2A antagonism

Rodent Cognition*
Improved reference memory (Morris water maze)

Unknown

Improved learning/consolidation (Y water maze task)

Unknown

* Improved cognition may be due to increased alertness

Long-Term Effects of Caffeine Intake
Behavioral Effect (Rodents). The locomotor disturbances induced by acute
doses of caffeine disappear after chronic caffeine administration. For instance, rats given
an acute dose of caffeine show decreased exploratory behavior in the open field task and
also show increased anxiety in the plus-maze test; yet after 21 days of chronic caffeine
administration both of these disturbances disappear (Bhattacharya et al., 1997). Another
study reported that tolerance to A1 receptor blockade is indicated for the lack of
consistent locomotor disturbances after caffeine intake in caffeine tolerant individuals
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(Karcz- Kubicha et al., 2003). Overall, these animal studies point to a minimizing or
complete loss of the motor effects of caffeine once tolerance develops.
The chronic administration of caffeine to rodents leads to adaptive changes that
abolish the cognitive changes seen during acute treatment of caffeine as well. Chronic
administration of the A1 selective receptor antagonist CPX for only 9 days resulted in a
tolerant adaptation that caused CPX to have no effect on the spatial learning and memory
of mice tested in the Morris water maze (Von Lubitz et al., 1993). Chronic caffeine
treatment for 15 days also had no effect on prevention of memory loss in trained rats
(Molinengo et al., 1994). Prior studies in wild-type rodents thus have shown that
administration of caffeine or specific adenosine receptor antagonists for approximately
two weeks results in no obvious effects on memory or learning, although no truly chronic
caffeine administration studies (that might relate to caffeine use in humans) have been
done investigating cognitive measures.
Behavioral Effect (Humans). Large population studies done to examine the
long-term effects of caffeine use on human memory have been controversial because of
the many variables that must be taken into account. For instance, Hameleers et al. (2000)
found in a cross-sectional study of 1875 adults participating in the MAAS study (the
Maastricht Aging Study) and ranging in age from 24-81 years that higher habitual
caffeine intake is significantly associated with faster response speed and improved longterm memory, yet no differences in short-term memory were found. In contrast, a
longitudinal study of the same MAAS group found no relationship between habitual
caffeine intake and verbal memory performance (van Boxtel et al., 2003). An earlier
study of 9003 British adults reported that aged individuals appear to be more receptive to
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caffeine’s cognitive boosting affects than younger individuals (Jarvis, 1993), thus
suggesting that the inclusion of younger adults in the MAAS studies may have provided
the confounding results.
Physiological Changes of Long-Term Caffeine Intake. The study by Maia and
Mendonca (2002) that suggested caffeine intake is associated with a lower risk for AD
has driven several studies to investigate caffeine’s antagonism of specific adenosine
receptors in the CNS, the more obvious effect of caffeine intake (Dall’Igna et al., 2004;
Dall’Igna et al., 2003) . These studies fail to fully account for the typical patterns of
caffeine consumption in humans however. Knowing that caffeine’s half-life in humans
can be less than 3 hours, it is reasonable to assume that the short term effects of caffeine
intake only exist for brief durations during the typical day. This makes it difficult to
attribute an overall protection against AD (which is progressively and continually
disrupting the normal brain physiology decades before any symptoms appear) to the
immediate blockade of adenosine receptors. It is therefore relevant to look to any long
term effects of caffeine as the main agent granting protection from AD. From this
standpoint, caffeine’s neuroprotective effect can be elucidated from several studies
indicating an effect of caffeine on adenosine modulation separate from acute receptor
antagonism. These are significant because relationships between impaired adenosine
levels and Alzheimer’s disease have already been implicated but not completely
explored.
It is particularly noteworthy that increased plasma levels of homocysteine, a
known risk factor for AD, are associated with decreased adenosine formation in plasma
taken from AD patients (Selley, 2004). Interestingly, increased levels of homocysteine
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are associated with normal aging, decreased physical activity, and diets high in animal
protein yet deficient in fruits and vegetables (Miner et al., 1997). These are all also risk
factors for AD.
At the molecular level, high levels of homocysteine interfere with the intracellular
production of adenosine by forcing the normal conversion of S-adenosylhomocysteine
(SAH) into adenosine and L-homocysteine to occur in reverse, thus sequestering
adenosine as SAH inside the cell (Fredholm et al., 1999; Fig.2). Indeed, high levels of
SAH have recently been identified in the brains of AD patients, and elevated levels of
SAH in AD patients have been shown to inhibit important methyltransferases in the brain
(Kennedy et al., 2004). Furthermore, the enzyme S-adenosylmethionine (SAM), which is
involved in the continuous conversion of methionine to homocysteine (Miner et al.,
1997), is found in decreased concentrations in Alzheimer’s disease (Morrison et al.,
1996; Morris, 2003; Mizrahi et al., 2003). The SAM enzyme has recently been identified
as a methyl donor to a promoter site on the PS1 gene resulting in decreased PS1
expression (Scarpa et al., 2003), and also is involved in the down-regulation of BACE (βsecretase) (Fuso et al., 2005) (Fig. 2).

Figure 2. Impact of elevated
levels of homocysteine on
SAM in AD
S-adenosylhomocysteine(SAH)

Homocysteine + Adenosine

PS1 and BACE
expression

S-adenosylmethionine (SAM)

Methionine
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Aβ Production

If high levels of homocysteine are present, either because of diet, vitamin
B12/folate deficiency, or advancing age; then it is likely that SAM methylation of PS1 and
BACE is blocked by the increased concentrations of SAH. Thus, decreasing methylation
by SAM may result in a rise in expression of the PS1 and BACE genes, leading to
increases in Aβ production. It has also been found through in vitro studies that a folic
acid deficiency and elevated homocysteine levels disrupt DNA repair in hippocampal
neurons, which sensitizes them to the toxic affects of amyoid accumulation (Kruman et
al., 2002). This information implies that increased homocysteine levels may play both a
direct and indirect role in Alzheimer’s disease, and represents a potential target for the
long-term effects of caffeine intake (see Figure 3).
Interestingly, a recent in vivo experiment found extracellular levels of adenosine
were elevated 8 hours after caffeine administration in rats (Conlay et al., 1997). The
authors proposed this increase may be a result of adenosine receptor blockade. However,
caffeine is the downstream precursor of a biosynthetic process in tea leaves that begins
with SAM (Koshiishi et al., 2001). Thus, caffeine intake may elevate SAM levels when it
is degraded. It is also possible that caffeine’s blockade of A2A receptors on astrocytes
leads to inhibition of COMT (catechol-O-methyltransferase), the enzyme responsible for
conversion of SAM to SAH. The elevation of SAM would lead to the decreased
expression of the genes that would otherwise lead to AD (see Figure 3) and might be
evident by increased adenosine levels as SAH was hydrolyzed to adenosine and
homocysteine.
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Figure 3. Proposed impact
of caffeine on the SAM/SAH
cycle in AD
S-adenosylhomocysteine(SAH)
Caffeine

-2-

Homocysteine + Adenosine

PS1 and BACE
expression

COMT

Aβ Production

-1-

S-adenosylmethionine (SAM)

Methionine

Tolerance to Caffeine
The long-term administration of caffeine results in the disappearance of the
behavioral side effects associated with caffeine intake (e.g. tolerance). Concordantly, this
should be the result of neuromolecular changes because of the fluctuating presence of
caffeine and elevation of adenosine levels. Indeed, numerous studies involving rodents
have reported that chronic treatment with caffeine, ranging from 4-28 days, results in
increased numbers of A1 receptors in both cortical (Tsutsui et al., 2004; Shi and Daly,
1999; Shi et al., 1993) and hippocampal neurons (Rudolphi et al., 1989; Johansson et al.,
1993). The mechanism for this increase remains unresolved, as none of these studies
reported changes in mRNA for the A1 receptor. Many of these studies examined A2a
receptors as well, but no changes were seen in receptor counts or mRNA levels (Shi and
Daly, 1999; Johansson et al., 1993; Shi et al., 1993). These findings suggest A1 receptors
are responsible for the development of tolerance to the behavioral and physiological side
effects of caffeine. Importantly, this increase in A1 receptor levels has implications for
potentially reversing trends seen in AD as well. Additionally, a 4-day treatment of
caffeine to mice also found an approximate 17% increase in the density of cortical L-type
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calcium channels, but the authors failed to suggest a mechanism for this and its
implications remain unknown (Shi et al., 1993).
The considerable 8 hour delay between caffeine administration and increases in
adenosine first noticed by Conlay et al. was later replicated and traced to the blockade of
A1 receptors (Andresen et al., 1999). The authors suggested the time lag between receptor
antagonism and increases in adenosine may be caused by new protein synthesis, posttranslational modifications, or reductions in the synthesis of key enzymes responsible for
metabolizing adenosine, such as adenosine deaminase. The authors go on to propose that
A1 receptors monitor extracellular levels of adenosine and when activated, influence
adenosine levels by potentially modulating the activity of adenosine deaminase.
Therefore the losses in hippocampal A1 receptors reported in patients with dementia
(Deckert et al.., 1998) and Alzheimer’s disease (Ulas et al., 1993) suggests impaired
monitoring of adenosine function in AD. If adenosine is being trapped intracellularly in
the form of S-adenosylhomocysteine, then the reduction of extracellular adenosine could
potentially lead to the reductions in its receptor as well. Given the likely role of APP in
axonal transport (Kamal et al., 2001) and accumulating Aβ interferes with fast
anterograde and retrograde axonal transport (Hiruma et al., 2003), it is also possible to
surmise impaired axonal transport may lead to the decrease in adenosine A1 receptors
seen in AD cases.
Diminishment of A1 receptor function would impair an innate neuronal pathway
that monitors Ca2+ homeostasis, which is known to be disrupted in neurons after long
term exposure to the Aβ1-42 isoform found in AD. As mentioned earlier, NMDA receptors
are found in abundance in the hippocampus making neurons in this area particularly
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sensitive to excitotoxic damage during pathological conditions. Therefore, it is likely that
the progression of AD leads to decreases in A1 receptor-mediated protective mechanisms
against excitotoxicity in both the cerebral cortex and hippocampus in combination with
the toxic affects of Aβ, creating a hostile environment for neurons in these brain areas.
An increase in A1 receptors following long term treatment of caffeine thus may reverse
this trend restoring A1 receptors to normal or above physiological levels.
Health Risks of Caffeine Intake
The impact of moderate caffeine intake on health has been scrutinized through
epidemiological studies with no clear detrimental affects. Caffeine’s relationship with
blood pressure is of particular concern, yet most studies report no association between
caffeine consumption and blood pressure in tolerant individuals (Chou and Benowitz,
1994; Robertson et al., 1984; Bertrand et al., 1978). Other studies have found an
association between caffeine and changes in blood pressure, but these findings are
considered controversial because they fail to distinguish between infrequent caffeine
users and habitual caffeine users (Rachima-Maoz et al., 1998). It has also been suggested
that hypertensive patients are more prone to the pressor effects of caffeine, although this
sensitivity was not found in a case study (Robertson et al., 1984). Moderate caffeine
intake is known to raise blood pressure in caffeine-naïve subjects and in subjects
abstaining from caffeine long enough to lose their tolerance to caffeine, yet this pressor
affect is only in the range of 2-3 mm Hg and this affect is lost within 24 hours after
tolerance appears (Myers, 2004). High intake of caffeine also can lead to tachycardia,
heart palpitations, and a small decrease in heart rate, but again these effects are
minimized after tolerances develops within days (Fredholm et al., 1999).
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The Joint National Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure expressed their view that restriction of caffeine intake
is not a recommended procedure on reducing blood pressure (Chobanian et al., 2003), yet
some doctors continue to recommend the elderly or people already prone to hypertension
avoid caffeine. If caffeine does have neuroprotective properties, it would be prudent
instead to recommend a moderate, sustained caffeine intake throughout life to reduce any
of the cardiovascular effects discussed previously that could appear if tolerance to
caffeine is lost during any abstinence from the drug.
Caffeine, as well as other methylxanthines, is a well known diuretic and
natriuretic that inhibits proximal tubular reabsorption by antagonizing renal A1 receptors
(Rieg et al., 2004). Finally, caffeine also raises the respiratory rate in the same, but yet
not as effective, mechanism as theophylline (the common bronchodilator prescribed for
asthmatics) (Benowitz, 1990). Caffeine also has weak self-reinforcing properties when
compared to the drugs of abuse, such as cocaine or heroine, and is not described as an
addictive substance in the Diagnostic and statistical manual of mental disorders (4th ed.).
Although symptoms such as headache and fatigue may accompany caffeine withdrawal
when caffeine intake is reduced significantly (Griffiths et al., 1990), none of the side
effects of prolonged, moderate caffeine intake have been linked conclusively to any
adverse health conditions.
Summary
Although blockade of A1 and A2A adenosine receptors produces some potential
immediate neuroprotective effects, it is likely that caffeine’s biggest contribution to
neuroprotection in Alzheimer’s disease may be the reinforcement of SAM methylation of
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PS1 and BACE. Given the nature of moderate caffeine consumption and its metabolism,
the short-term neuroprotective effects of caffeine would certainly not exist long enough
to have any lasting contribution against the lifelong onslaught of AD. Although it has yet
to be determined exactly how caffeine raises SAM levels, several possibilities exist. First,
caffeine is a xanthine derivative of SAM, and once metabolized may provide extra
substrate for the synthesis of SAM, leading to the increased formation of this compound.
Caffeine may also inhibit COMT activation, which would decrease astrocytic
homocysteine synthesis (Huang et al., 2005) and reduce SAM conversion to SAH.
Regardless, the chronic use of caffeine generates a rise in SAM that likely leads to
diminished expression of genes that are known to be overexpressed in familial
Alzheimer’s disease and are likely askew in sporadic AD, resulting in decreased
production of Aβ and prevention of the corresponding changes in neuropathology.
Ideally, changes in expression of these genes is minimal but sufficient enough to slow
down Aβ production thus avoiding many of the negative side effects of other therapeutics
designed to minimize expression of these genes. It is also possible that diminished
production of Aβ allows for innate protective mechanisms in the body to equilibrate the
clearance and production of Αβ. Caffeine may also be effective in reversing the decreases
in hippocampal A1 receptors seen in AD and aging through mechanisms that develop as
tolerance in response to chronic caffeine intake, ultimately restoring the endogenous
protective pathway against alterations in Ca2+ or excitotoxicity.
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IV. Specific Aims
Overexpression of the hAPP gene with the “Swedish” double mutation in APPsw
mice results in impaired reference/learning memory and impaired working memory by 89 months of age that closely mimics the cognitive decline seen in Alzheimer’s patients.
These behavioral impairments are certainly linked to the appearance of Aβ species, but
other pathological changes must also be taken into consideration as well when evaluating
the full scope of the disease. The decrease in A1 adenosine receptors found in the brains
of late Alzheimer’s patients may be a marker for other important disruptions in the brain,
especially considering adenosine’s relationship with homocysteine/SAH/SAM and its
potential indirect impact on enzymes reported to decrease expression of genes involved in
AD. SAM-related changes have yet to be examined in animal models for Alzheimer’s
disease, so it is therefore relevant to see if there are any differences between APPsw and
non-transgenic mice.
Caffeine use has been implicated with the occurrence of Alzheimer’s disease,
with moderate caffeine intake decreasing the risk for the disease. Additionally, caffeine
use has been shown to increase cortical and hippocampal A1 receptors and raise
extracellular adenosine levels in blood plasma. If this occurs in the brain, it may further
support the link between impaired SAM function and Alzheimer’s disease. I propose that
APPsw mice will have decreased cortical and hippocampal A1 receptors and subsequently,
will also have reduced extracellular brain adenosine and S-adenosylmethionine levels in
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the brain. These APPsw mice will also be cognitively impaired because of increased levels
of soluble Aβ. Furthermore, long-term administration of a moderate caffeine dose to
APPsw mice will reverse these effects, ultimately reducing amyloid load in these mice and
restoring cognitive function.
The specific aims of my research proposal are:
•

To behaviorally characterize a group of APPsw and Tg- control mice in a full
battery of sensorimotor and cognitive tasks to determine the degree of behavioral
impairment these mice develop at 8 months of age.

•

To determine the behavioral effect a 4 month treatment of oral caffeine
(beginning at 4 months of age) has on a similar group of age-matched 8 month old
APPsw transgenic mice.

•

To explore any differences in SAM and adenosine between non-transgenic and
APPsw mice.

•

To evaluate the relationship between long-term caffeine administration in a mouse
model of Alzheimer’s disease and any changes in amyloidogenic processing in
the CNS as a result of caffeine treatment.

•

To determine the relationships between brain Aβ levels, brain adenosine receptor
levels, and cognitive performance in APPsw and caffeine-treated APPsw transgenic
mice.
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V. Materials and Methods
Animals
57 mice were included in this study. Each mouse had a mixed background of
56.25% C57, 12.5% B6, 18.75% SJL, and 12.5% Swiss-Webster. All of these mice were
derived from a cross between P (parental generation) heterozygous male mice carrying
the mutant APPK670N, M671L gene (APPsw) with F1 PS1 (transgenic line 6.2) female mice to
obtain an F2 generation consisting of APP/PS1, APPsw, PS1, and non-transgenic mice.
After weaning, the mice were genotyped with only APPsw and non-transgenic mice
selected for behavioral testing and/or caffeine administration. These mice were then
group housed in cages with rodent chow and water or caffeinated water ad libum. All
mice were maintained in a 10 hour dark and 14 hour light cycle at all times, and all
behavioral testing was performed during the light cycle.
Effects of Long-Term Caffeine Administration in Young Adult APPsw Mice
General Protocol
A total of 41 single transgenic APPsw mice and 16 non-transgenic (NT) littermates
were randomly selected for this study. 14 APPsw mice were randomly selected from the
APPsw group and were administered caffeine treatment in drinking water beginning at 4
months of age. The remaining 27 transgenic mice, as well as 16 non-transgenic
littermates, were provided normal water to serve as Tg and NT controls. All mice were
removed from group housing and moved to single housing two weeks before behavioral
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testing began. Behavioral testing began at 8 months of age (four months into caffeine
treatment) and consisted of a 6-week battery that was composed of 3 sensorimotor-based
tasks, one anxiety-based task, and five cognitive-based tasks. These tasks were performed
in the following order: open field activity, balance beam, string agility, Y-maze, elevated
plus maze, Morris water maze, circular platform, platform recognition, and radial arm
water maze. All mice were euthanized following completion of behavioral testing and
brains were removed for further analysis. This analysis consisted of quantification of
brain soluble/insoluble Aβ levels, determination of both α- and β-CTFs, and assessment
of brain adenosine receptor densities. Fig. 1 depicts a timeline for this study. Mice were
weighed every two weeks to ensure no changes in weight occurred from the caffeine
treatment.

Study Timeline
6-Week Behavioral Battery
Oral Administration
of Caffeine

Animals Born

Animals
Sacrificed

0

4

8

Months
Fig 4. General protocol time line for long-term caffeine administration study.
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Caffeine Treatment
At 4 months of age, 14 APPsw group housed mice were given ad libum access to
only water with 0.3 mg/mL caffeine (Sigma) dissolved in it. On average, mice drink 5 mL
per day, giving a daily dose of 1.5 mg of caffeine to each mouse. Given that metabolic
rate (MR) =Mass-¼, the MR of mice (average weight = 0.025kg) is 7.2 x greater than
humans (average weight = 68kg). Thus, a 1.5 mg daily dose in a mouse is equivalent to
an approximately 500 mg daily caffeine intake (~5 cups of coffee) by a human. The
caffeinated water was changed two times a week to ensure caffeine remained fully
dissolved at the appropriate concentration. Control APPsw and NT mice were given ad
libum access to untreated tap water that was also changed twice weekly to ensure
freshness. Mice were kept under these conditions for 3½ months, at which point they
were separated into single housing, two weeks before behavioral testing began (Fig. 1).
Caffeine treatment was continued throughout this time and during behavioral testing. The
weights of the animals were monitored throughout this study to ensure no significant
weight reductions occurred.
Behavioral Assessment
Over a 6-week time course, mice were behaviorally tested for characterization of
their sensorimotor, anxiolytic, and cognitive functions utilizing the following tasks and in
the order described:
Open-Field Task. This test assessed exploratory behavior and activity by
placing mice into an unfamiliar open black box (81 x 81 cm) with 28.5-cm walls. The
bottom of the box was marked by 4 horizontal and 4 vertical lines, dividing the surface
into 16 squares. The task consists of a single trial, wherein a single mouse is placed in the
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center of the field and allowed to explore for 5 minutes. During this period, each line
crossing was recorded. Before each trial, the surface of the box was sprayed with a
diluted vinegar solution to erase any scent cues.
Balance Beam Task. The balance beam consists of a 1.1-cm-wide dowel beam
suspended 43 cm above a padded surface. Flanking each end of the 51-cm-long dowel are
14 x 10.2 cm platforms. Each animal was placed perpendicular to the dowel at the center
of the beam and released for an interval of 60 seconds. The duration the animal was able
to stay on the balance beam was recorded. If the animal remained on the balance beam
for the full time and/or escaped to one of the platforms, the maximum score of 60
seconds was recorded. Each mouse’s balance and general motor function was evaluated
by subjecting the animals to 3 trials, with the overall average indicating the best
approximation of the mouse’s performance.
String-Suspension Task.

This task is an additional sensorimotor test used to

characterize the agility and grip strength of mice. Animals were allowed to grip the string
with only their forepaws and released for a single trial of 60 seconds. Each animal was
scored on a 0-5 rating system (0=animal was unable to stay on the string; 1=animal was
able to hang onto the string for 60 s by only two forepaws; 2=was given if the animal was
able to hang onto the string by two forepaws and one hind limb; 3= animal remained on
the string for 60 s and gripped the string by two forepaws and both hindpaws, 4=animal
was able to grip the string with four paws and its tail; 5=was given if the mouse escaped
from the string to one of the support columns.
Y-Maze Task. This task was used to assess basic mnemonic processing (by
spontaneous percent alternation) and exploratory activity (by total number of arm
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choices) of mice placed into a black Y-maze. The arms of this maze were 21 cm-long and
4 cm-wide with 40 cm-high walls. Each mouse was placed in the center of the maze,
facing the arm designated number two and allowed one five minute trial of free
exploration of the three alleys in the maze. The number of total arm choices and sequence
of arm choices were recorded. Alternation percentage is defined by the proportion of arm
choices that differ from the last two choices. For instance, if a mouse selected the
following sequence of arm choices (1,2,3,1,3,1,2,1), the total number of alternation
opportunities would be six (total entries minus two) and the percentage alternation would
be 50% (three of six). Before each trial, the interior of the maze was spray with a diluted
vinegar solution to erase any scent cues.
Elevated Plus-Maze.

The elevated (+)-maze was used to assess anxiety in mice.

The task has four arms (30 x 5 cm) attached to a 5 x 5 cm central area, all made of
plywood and painted black. Two opposite facing arms were unenclosed and open to the
surrounding environment. The other two opposite facing arms were enclosed by black
aluminum sheet walls (15-cm height). This entire structure sits on a wooden pedestal,
elevated 82 cm above the floor level. Each mouse was placed into the center area facing a
closed arm and allowed to explore the plus-maze for a single five minute trial. The
number of closed and open arm entries, and the amount of time spent in open arms was
recorded. Before each trial, the maze was cleaned with a diluted vinegar solution to erase
any scent cues.
Morris Water Maze. This water-based task was used to evaluate spatial
reference learning/memory of the mice. A 100-cm circular inflatable pool was divided
into four equal quadrants by black lines drawn on the floor of the pool; an indiscernible
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9-cm platform was submerged 1.5 cm below the water’s surface in quadrant two. The
environment surrounding the pool was decorated with eye-catching visual cues to aid the
mice in orientating themselves with respect to the pool. Each mouse was subjected to
four trials a day over a 10 day period. Each trial began by placing the mouse into a
different quadrant and allowing it to swim freely for a maximum of 60 seconds. The same
quadrant start pattern was used each day. After swimming to the platform (or being
guided to the platform if the mouse was unable to locate the platform after 60 s), the
animal was allowed to remain on the platform for 30 s before starting the next trial. The
latency for each animal to locate the platform in all four trials and the average for all
trials was recorded. After the tenth day of acquisition testing, a 60 s probe trial was
performed the following day to determine memory retention. For this single trial, the
submerged platform was removed and each mouse was placed into the quadrant opposite
to the quadrant that formerly contained the platform in acquisition testing. The animal’s
swim path and number of annulus crossings were recorded on videotape; the percent of
time spent in each quadrant, as well as average swim speed, were determined from these
videotapes.
Circular Platform Task.

This task tests reference learning/memory by placing

the mice in a curtain-enshrouded 69-cm circular platform with 16 holes (4.5 cm diameter)
equally placed 1.3 cm from the outside edge. The holes designated 4, 8, 12, and 16
allowed the placement of an escape box directly underneath the hole. Two-dimensional
cues were placed on the inside walls of the enclosing curtain, as well as on the platform’s
walls. The aversive light and wind stimuli used to motivate mice to escape the platform
was provided by two 150-W lamps placed 76 cm above the platform and a high-speed fan
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placed 15 cm above the platform. The first day of the circular platform task consisted of
shaping (wherein mice were placed into the center of the platform and gently guided to
the location of their escape platform), with the following eight days designated for actual
testing. The mice were subjected to a single trial each day that consisted of placing each
mouse in the center of the platform and allowing it a 5 minute maximum to locate and
enter the escape box. During the testing period, the total number of errors (head pokes
into non-escape holes) and the latency to escape from the platform were recorded. The
surface of the circular platform was cleaned after each trial with a dilute vinegar solution
and the escape box location was moved to a different location after each mouse’s trial to
control for any scent cues (although the box remained in the same location for each
particular animal over the eight days of testing).
Platform Recognition Task. This water-based task characterizes the ability of
the mice to escape to a visible platform in changing locations placed in the same 100-cm
inflatable water pool used in the Morris water maze. A delayed latency to escape
indicates a potential deficit in visual acuity or, more likely, an impaired ability to switch
strategies from a spatial cued strategy used in the Morris water maze to a
search/recognition strategy needed for this test. In this task, a 9-cm circular escape
platform was elevated 0.8 cm above the surface of the water with an affixed 10 x 40 cm
black and white visual cue to clearly mark it as the escape platform. Performance was
evaluated over four days of testing, with 4 trials per day. Each day, the mice were placed
in the pool at the same location for each trial, but the platform was moved successively to
a new quadrant for each of the four trials. If a mouse was unable to locate the platform in
the 60 s provided, it was gently guided to the platform. A 30 s rest period was given to
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each mouse on the platform. Latency to find the platform was recorded over all 4 trials
each day, which were averaged for statistical evaluation.
Radial Arm Water Maze (RAWM).

This final water-based task requires the mice

to have intact working (short-term) memory and is the most stringent for determining
cognitive deficiencies. The RAWM maze incorporated the same 100-cm circular pool
used previously, but also used an aluminum insert that creates 6 equal-sized radial arms
surrounding a central open swimming area 40 cm in diameter. Each arm was 30.5 cm
long and 19 cm wide, and a transparent 9 cm circular platform that rests 1.5 cm below the
water’s surface was placed near the end of the randomly assigned goal arm of the maze
for each day. The same spatial cues used in the Morris water maze were provided on the
walls surrounding the RAWM task throughout testing. Each day of RAWM testing
consisted of four acquisition trials and one memory retention trial. RAWM testing was
conducted over nine successive days. For each acquisition trial, a mouse was placed in
the water at the entrance of a novel start arm of the maze for that day facing the central
swimming area. This start arm was never the same arm that contained the submerged
escape platform, and the start arm sequences and goal arm location were semi-randomly
selected each day. The mouse was then allowed to navigate the maze for 60 seconds.
During this 60 s, if the mouse chose the wrong arm (that did not contain the escape
platform) it was gently guided back to the start arm to renew navigating the maze and an
error was recorded. If a mouse fails to select an arm within 20 seconds, it was gently
guided back to the start arm and an error was recorded. If the animal failed to find the
platform at the end of 60 s, it was gently guided to it. Once locating the platform, the
mice were allowed a 30 s rest period. The latency to escape the maze and the number of
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wrong arm choices were recorded over all four successive acquisition trials. Upon
completion of the fourth acquisition trial, the mice were returned to their home cage for a
30 minute interval before being returned to the pool for the fifth and final trial of the day,
the memory retention trial. The last trial of the four successive trials (trial 4, T4) and the
30-minute delayed retention trial (trial 5, T5) are considered measures of working
memory. Any mouse that did not make at least 3 choices during a trial and were unable to
locate the escape platform had a penalty assessed for that trial. This penalty was
calculated by averaging trial one errors for the first three days of testing for animals
which could not find the escape platform but made more than three arm choices during
those trials. For this study, the penalty error assessed was 7.1.
Brain Collection
Immediately following completion of behavioral testing, all mice were
anesthetized with Nembutal (1mg/10 gm body weight), then pericardially perfused with
0.9% saline. Brains were then removed and split into halves by a single mid-saggital cut.
The left hemisphere was fixed in 4% paraformaldehyde for 24 hours at 4°C, followed by
graded sucrose solutions (10, 20, and 30% (w/v) sucrose in 0.1 x Sorenson’s phosphate
buffer). The right hemisphere was dissected out into the following areas: cerebellum,
anterior and posterior cortex, striatum, and hippocampus. These areas were immediately
frozen on dry ice and stored at -80°C. For half the animals in each group, the right frontal
cortex, striatum, and hippocampus were used to measure the densities of adenosine
receptors. For the remaining half of animals in each group, the right hippocampus was
used to determine levels of soluble/insoluble Αβ and combined right frontal + posterior
cortex was used for analysis of α- and β-carboxyl terminal fragments.
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Analysis of β- and α- CTFs (carboxyl terminal fragments)
This procedure was performed by Dr. Jun Tan and Kavon Rezai-zadeh. Frontal
and posterior cortices were thawed, combined, and placed in ice-cold lysis buffer (20
mM Tris, pH7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% v/v Triton X-100, 2.5
mM sodium pyrophosphate, 1 mM β-glycerolphosphate, 1 mM Na3VO4, 1 µg/mL
leupeptin) with 1 mM PMSF. Brain tissues were then sonicated on ice for approximately
3 mins, cooled on ice for 15 mins, and then centrifuged at 15,000 rpm for 15 mins.
Following homogenization, aliquots corresponding to 50 µg of total protein were
electrophoretically separated using 16.5% Tris-tricine gels. Electrophoresed proteins
were then transferred to PVDF membranes (Bio-Rad), washed in dH2O, and blocked for
1 hr at room temperature in Tris-buffered saline (TBS; Bio-Rad) containing 5% (w/v)
non-fat dry milk. After blocking, membranes were hybridized for 1 hr at room
temperature with primary antibody [APP-carboxyl-terminal antibody 369(1:1000)].
Membranes were then washed 3 times for 5 min each in dH2O and incubated for 1 hr at
room temperature with the appropriate HRP-conjugated secondary antibody (1:1,000,
Pierce Biotechnology, Inc. Rockford, Illinois). All antibodies were diluted in TBS
containing 5% (w/v) non-fat dry milk. Blots were developed using the luminol reagent
(Pierce Biotechnology). Blot intensities were analyzed qualitatively and assessed a ratio
of 2:1 or 1:1 depending on their intensities in relation to each other (β-CTF vs. α-CTF).
Adenosine Receptor Densities (Completed by Dr. Edward Jackson)
Western Blotting. The tissues were placed in eppendorf tubes with 0.1mml SDS
buffer (50mMTris, ph 7.0, 2% SDS, 10% glycerol) containing protease inhibitors
(2µg/ml antipain, 1 ug/ml aprotinin, 2 ug/ml leupeptin, 1 mg/ml phenylmethylsulfonyl
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fluoride) and homogenized with a small plastic pestle in ice. The homogenate was
centrifuged at 12,000 rpm at 4’C for 10 min, and the supernatant was recovered. Protein
in the supernatant was terminated by the copper bicinchoninic acid method. Laemmli
buffer was added to samples, after which they were placed in boiling water for 5 min and
then chilled immediately on ice. 15 µg protein/well samples were loaded onto a 7.5-10%
acrylamide gel and subjected to SDS PAGE using the Bio-Rad minigel system. Proteins
were then electroblotted onto a polyvinylidine difluride membrane. The membrane was
blocked with 5% milk for 1h and incubated at 4’C overnight with the first antibody (antiA1 1:1000 diluted in PBS containing 0.5% Tween 20; anti-A2a 1:1000 diluted in PBS
containing 0.5% Tween 20, antibodies were from Santa Cruz). After three washes with
PBS containing 0.5% Tween 20, the membrane was incubated at room temperature for 1h
with HSP-conjugated secondary antibody (Amersham) at 1:10,000 dilution. The
membrane was exposed to film and the signals were detected by a supersignal substrate
kit (Pierce).
RT-PCR. Total RNA was isolated using Trizol reagent solution (GIBCO). By
using the primer sequences listed in Table 2, 0.5 µg RNA was reverse transcribed and
amplified using a Titanium One-Step RT-PCR Kit (Clontech). Each PCR cycle (a total of
30 cycles for A1 and 32 cycles for A2a) consisted of denaturing at 94°C for 30 s,
annealing at 64°C for 30 s, and extension at 72°C for 60 s. The products were separated
on a 1% agarose gel with EB staining and the signal was detected by UV.
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Table 2. Mouse adenosine receptor PCR primers and cDNA sizes
Receptor Accession No. Primer Nucleotides
Sequence 5’-3’
Product
Size
A1
NM_009629 Forward
659
TAGGGCAACGCCTTTGGGAC
849
Reverse 1507
ATGGGTGTCAGGCCTACCAC
A2A
NM_009630 Forward
177
GCCATCACCATCAGCACTGG
734
Reverse 910
TCAGGACGTGGGTTCGGATG
The band densities were quantitatively measured using Scion-image software.
Background signals were obtained in each lane and subtracted from the band densities to
correct for the background signal.
Effects of Caffeine Administration in Aged APPsw Mice
General Protocol
At 17 months of age, 8 APPsw mice and 3 non-transgenic (NT) littermates were
randomly selected to determine the effect of caffeine administration on both extracellular
brain levels of adenosine and soluble/insoluble brain Aβ levels.
Four APPsw group-housed mice were given ad libum access to water with 0.3
mg/mL caffeine (Sigma) dissolved in it, as per the long-term study. Four APPsw mice and
three NT group-housed mice were not administered caffeine in their drinking water and
thus served as controls. Mice were kept under these conditions for 18 days, at which
point they were euthanized (Fig. 5) and brains were removed for quantification of
extracellular brain adenosine levels, soluble/insoluble Aβ levels, γ-secretase activity, and
S-adenosyl methionine (SAM) levels. The weights of the animals were monitored
throughout this study to ensure no significant weight reductions occurred.
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Study Timeline
Oral Administration
of Caffeine
Animals
Sacrificed

17

17.5

18

Months
Fig. 5. General protocol time line for caffeine administration in aged mice.
Brain Collection
Immediately following caffeine treatment, all mice were anesthetized with
Nembutal (1mg/10 gm body weight). Each mouse’s skullcap was surgically removed and
the brain was quickly excised and split into halves by a single mid-saggital cut. The left
hemisphere was rapidly snap-frozen in liquid nitrogen and reserved for measurement of
extracellular brain adenosine levels through HPLC. This technique was done quickly to
protect the tissue from ischemic conditions which would disrupt any adenosine
measurements. The right hemisphere was dissected out into the following areas:
cerebellum, anterior and posterior cortex, striatum, and hippocampus. These areas were
immediately frozen in dry ice and stored at -80°C. Later, the hippocampus was used to
measure the levels of soluble and insoluble Aβ through ELISA. Combined anterior and
posterior cortices were later analyzed for both γ-secretase activity and S-adenosyl
methionine levels.

66

Measurement of Brain Adenosine Levels (Completed by Dr. Edward Jackson)
Sample Preparation. Half brains were weighed (50-60 mg) and washed with
500µL cold phosphate-buffer saline (PBS). Tissue was transferred to a centrifuge tube
containing 500µL water and then boiled for four minutes to inactivate adenosine
deaminase (and any other enzymes present in the sample). The tissue was then
homogenized in a power homogenizer and centrifuged at 14,000 rpm for five minutes.
The supernatant was drawn off and centrifuged a second time. The resulting supernatant
was loaded onto centrifugal filter devices (Biomax-30, Millipore) and filtered to remove
proteins. The filtrate was diluted 1:200 in water and internal standard (adenine 9-β-D
arabinofuranoside) was added to a final concentration of 10 pg/µL. The standard curve
was created in water and the samples were analyzed with an LCMS assay.
Mass Spectrometry. The assay was developed using a Thermofinnigan HPLC
system coupled to a Thermofinnigan LCQ Duo ion trap mass spectrometer equipped with
an electrospray ionization source (ESI). The mass spectrometer was operated in the ESI
positive ion mode. The analytes were monitored using single ion monitoring; for
adenosine and adenine 9-β-D arabinofuranoside (internal standard), the m/z was 268.
Measurement of γ-Secretase Activity (Collaboration with Kavon Rezai-zadeh)
Brain samples consisting of combined frontal and posterior cortices were placed
in ice-cold lysis buffer (20 mM Tris, pH7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA,
1% v/v Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerolphosphate, 1 mM
Na3VO4, 1 µg/mL leupeptin). Brain tissues were then sonicated on ice for approximately
3 mins, cooled on ice for 15 mins, and then centrifuged at 15,000 rpm for 15 mins. No
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PMSF was added to these samples as it may disrupt the activity of γ-secretase. Cell
lysates from these samples were then analyzed for γ-secretase activity using a γ-secretase
kit provided by R&D Systems, Inc.. Following the manufacturer’s protocol, a secretasespecific peptide conjugated to reporter molecules EDANS and DABCYL was added to
each cell lysate. Cleavage of this peptide by the γ-secretase present from each cell lysate
results in a fluorescent signal that is proportional to the level of secretase enzymatic
activity. Fluorescent signals were detected using a fluoromentric reader. Protein
concentrations were quantified to ensure equal protein levels were present in each
sample.
SAM (S-adenosyl-methionine) Quantification (Collaboration with Kavon Rezai-zadeh)
The same cortical homogenates used for γ-secretase activity were also used for
SAM quantification. SAM was quantified in these samples using a Bridge-It SAdenosyl-Methionine (SAM) Fluorescence Assay provided by Mediomics, LLC.
Following the manufacturer’s protocol, 10µl of each sample were added to a
polypropylene Eppendorf tube. 90µl of SAM assay solution was added to each sample
and vortexed for ~1 second. Then, 90 µl of the resultant mixture from each sample was
loaded in a black microplate, covered and incubated in the dark for 30 minutes. The
fluorescent intensity was then measured using a fluorescent microplate reader (settings:
excitation ~485 nm; emission ~665 nm). By using the standard curve generated by the
fluorescence of known SAM levels, the concentration of SAM in unknown samples was
calculated by its fluorescent intensity. Protein concentrations were quantified to ensure
equal protein levels were present in each sample.
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Determination of Soluble/Insoluble Aβ Levels
Tissue Homogenizing/Extraction. To determine the levels of both
soluble/insoluble Aβ(1-40) and Aβ(1-42), the hippocampi from mice in each group (6
Tg+caff, 6 Tg+, 1 NT from Study A and 3 Tg+caff, 3 Tg+, 1 NT from Study B) were
homogenized in tissue homogenization buffer (THB) (250mM sucrose, 20mM tris-HCl,
1mM EDTA, 1 mM EGTA, and protease inhibitor). 0.4% diethylamine (DEA; in 100
mM NaCl) solution was added to each homogenate and each sample was then centrifuged
at 100,000 x g for one hour. The supernatant from each sample was drawn off and stored
at -80°C for later quantification of soluble Aβ levels. Formic acid (FA) was then added to
the remaining pellet and samples were sonicated for one minute. Following sonification,
samples were spun down at 100,000 x g for one hour. The intermediate phase was drawn
off, and added to a FA neutralization solution. These FA-extracted solutions were
designated for quantifying insoluble Aβ levels and stored at -80°C.

Αβ (1-40) and (1-42) ELISA. Sandwich ELISA kits for both Aβ (1-40) and (142) were utilized (Signet laboratories). All extracts were thawed and appropriately diluted
to ensure results within the standard curve for each kit. Plates were coated with capture
antibodies specific to the amino-terminus for either the Aβ peptide (1-40) or (1-42),
depending on which kit was being used. Before loading the samples, each plate was
washed three times in a wash diluent. The standard curve (consisting of samples with
known amounts of Αβ peptide) and each brain sample extract were run in duplicate and
averaged to obtain the most accurate results. After loading the samples, the plate was
incubated at 4°C overnight and was washed three times the next day to remove unbound
peptide. A primary antibody was then added that binds to the carboxy-terminus of the
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peptide and allowed to incubate for two hours. After washing, a secondary antibody
conjugated to horseradish peroxidase was added to bind to the primary antibody and
allowed to incubate for another two hours. The plate was again washed and an Ophenylenediamine (OPD)-substrate was added to each well that visualizes the bound Aβ
peptide by reacting with horseradish peroxidase. This reaction occurred for 45 minutes, at
which point a stop solution was added and the plate was read at an absorbance of 490 nm.
The optical density (OD) for each sample was measured and compared to the OD of the
standard curve, allowing for the quantification of bound Aβ (either 1-40 or 1-42
depending on which kit was used) in each well.
Statistical Analysis
Behavior. Standard one-way ANOVAs were performed using Statistica software
to determine inter-group behavioral comparisons between APP mice, caffeine-treated
APP mice, and NT mice in the open-field, balance beam, Y-maze, elevated plus-maze,
Morris water maze acquisition and probe trial, circular platform, platform recognition,
and radial arm water maze (RAWM) tasks. Post-hoc pair-by-pair differences between
groups (planned comparisons) were later determined by the Fisher LSD test. Two-way
repeated measure ANOVAs were also performed to elucidate any behavioral differences
in groups in the multi-day tasks across days (platform recognition) and blocks (3-day
blocks for RAWM or 2-day blocks for Morris water maze acquisition). Mann-Whitney
U-tests for non-parametric data were performed to compare performance of mice in the
string agility task. RAWM swim speed was calculated by averaging overall T4+T5
latency and dividing by the average of overall T4+T5 errors. Any animals that were
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consistently unable to complete any task (e.g., floaters, circlers) were eliminated from
statistical analysis.
Pathology. Group comparisons for insoluble/soluble Aβ, adenosine receptor
measurements, secretase activity, SAM levels, and brain extracellular adenosine levels
were done by standard one-way ANOVAs. After ANOVA analysis, post-hoc pair-by-pair
differences between groups were analyzed with the Fisher LSD test. Correlation analysis
was also performed using Systat software to elucidate any potential relationships between
the behavioral, Aβ pathology, and brain adenosine measures.
Factor/Discriminant Factor Analysis. Factor analysis (FA) was performed using
Systat software to group all behavioral measures into common factors. This allows for the
relationship between individual behavioral measures to be determined, and also might
indicate potential performance in a task based on previous performance in another task.
This FA was performed using all 19 behavioral measures from all groups (NT, APPsw,
and APPsw+Caffeine) in this study.
To investigate if a relationship exists between behavioral and Aβ pathological
measures, correlation analysis was performed using Systat software. Correlation analyses
were performed between all 19 behavioral measures and all four Aβ measures.
Correlation analyses were also performed between all 19 behavioral measures to
determine if any inter-task relationships existed. Finally, correlation analysis was also
performed to determine the relationship between extracellular brain adenosine levels and
the four Aβ measures.
Additionally, discriminant factor analysis (DFA) was run using Systat software
with two different DFA methods (direct entry and stepwise-forward) using all 19
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behavioral measures and also only the 8 cognitive-based measures that loaded from
Factor 1. These DFA’s determined if the three groups of mice were behaviorally distinct
from one another. The direct entry method used all 19 behavioral measures, or the 8
measures from Factor 1 of FA, while the stepwise-forward method started with 19 or 8
measures, respectively, but selected from these measures based on their variance to best
differentiate between the three groups.

VI. Results
Weight Analysis. Throughout the study, mice in all three groups were weighed
every two weeks to ensure no significant differences occurred from the four month
caffeine treatment. Before the start of the caffeine treatment, there were no group
differences in weight between the transgenic and non-transgenic mice. Additionally, there
were no group differences between the NT, Tg, and Tg+Caff mice at the end of
behavioral testing when the animals were euthanized. Repeated measures analysis
revealed no group by time interaction [F(13,260)=0.66; p=0.89], indicating NT, Tg, and
Tg+Caff mice all gained weight at a similar rate during the entire four month period of
treatment.
Behavior- Sensorimotor Evaluation
Open Field and Y-Maze Entries. Tg mice exhibited increased open field activity
(Fig. 6a) when compared to NT controls (p<0.05), while activity of Tg+Caff mice was
not differ from NT mice at 8 months of age. Furthermore, both Tg and Tg+Caff mice
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made significantly more total arm choices in the Y-maze task (Fig. 8a), another measure
for activity/exploration, when compared to NT mice (p<0.02 for both groups).
Balance Beam. In balance beam testing, there were no group differences
between the mice (Fig. 6b), indicating that all mice had similar balance ability and intact
general motor function.
String Agility. In the string agility test (Fig. 6c), the Tg+Caff mice were less
agile than the Tg and NT mice (p<0.05), although this difference was simply because less
Tg+Caff mice escaped the string (score of 5) than the other two groups. As Tg+Caff mice
averaged a ranking of 4 in this task, they managed to cling to the string with all limbs for
the full 60 seconds and did not fall. Therefore, the difference does not imply a motor
impairment in Tg+Caff mice. The treatment-related impairment was task specific and,
moreover, did not influence performance in the cognitive-based tasks (see correlation
analysis).
Elevated Plus-Maze Anxiety. There were no group differences in open and
closed arm entries (Fig. 7b and c). Tg mice, but not Tg+Caff mice, spent more time in
open arms when compared to NT mice (p<0.05; Fig. 7a).
Behavior- Cognitive Evaluation
Y-Maze Alternation. In Y-maze testing for spontaneous alternation behavior,
there were no group differences in percent alternation (Fig. 8b). Tg mice were
unimpaired in this task, thus any protective effect from the long-term administration of
caffeine was not possible.

73

a)

Open Field

Line Crossings

200

*

160
120
80
40
0

b)

NT Tg Tg+Caff

Balance Beam
40

Seconds

30
20
10
0

c)

NT

Tg Tg+Caff

String Agility
5

**

Ratings

4
3
2
1
0

NT

Tg Tg+Caff

Figure 6. Open field, balance beam, and string agility performance. Tg mice
showed increased activity in the open field task. Tg+Caff mice had decreased
performance in the string agility task, but did not have any general motor impairment. * =
significantly different from NT group at p<0.05, ** = significantly different from both
other groups at p<0.05.
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Figure 7. Elevated plus-maze performance. Tg mice spent significantly more time in
the open arms than NT mice, while Tg+Caff mice were no different than NT mice. * =
significantly different from NT group at p<0.05.
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Figure 8. Y-maze performance. Both Tg and Tg+Caff mice had significantly more
arm entries than NT mice. * = significantly different from NT group at p<0.02.

76

Morris water maze acquisition. Escape latency data from this task were divided
into five 2-day blocks. There was no overall group effect across all five blocks
[F(2,50)=1.69; p=0.19] (Fig. 9). However, a strong group by block interaction was
evident [F(8,200)=3.51; p=0.0008], which was clearly due to the inability of Tg mice to
improve acquisitional performance after the second block of testing. Post hoc analysis of
individual blocks revealed NT and Tg+Caff mice showed a strong learning effect in the
last two blocks acquisition, resulting in significantly faster escape latencies when
compared to Tg mice (Fig. 9). Not surprisingly, Tg escape latencies on the last day of
testing were also significantly higher than NT and Tg+Caff escape latencies (p<0.5 and
p<0.02, respectively. Thus, the long-term administration of caffeine protected against
Morris maze acquisitional impairments that would otherwise be present in APPsw mice at
this age.
Results from the Morris maze probe trial are consistent with the protective effect
of caffeine treatment in APPsw mice during acquisition (Fig. 10). Tg mice showed no
quadrant preference during this spatial memory retention phase of testing. By contrast,
Tg+Caff mice showed an exclusive preference for the quadrant formerly containing the
submerged platform (Q2) and spent significantly more time in this quadrant than
Tg mice (p<0.025). NT mice showed only a partial preference for Q2, although their
percent time spent in Q2 was not statistically different from that of Tg+Caff mice.
Tg+Caff mice also made significantly more annulus crossings than Tg mice (p<0.005;
Fig. 10), giving further support for a protective effect of caffeine treatment in spatial
memory retention.
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Figure 9. Morris water maze acquisition latencies. The 10 days of acquisition, as
measured by latency to find a submerged platform, are presented in five 2-day blocks. Tg
mice were significantly impaired in spatial reference learning in blocks 4 and 5, while
Tg+Caff mice performed no different than NT mice. † = Tg mice had significantly higher
escape latencies than both other groups at p<0.05 or higher level of significance.
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Figure 10. Probe trial testing for reference memory retention in the Morris water
maze. Tg+Caff mice showed an exclusive preference for the quadrant formerly
containing the submerged platform (Q2). This preference is also indicated by the
significantly higher number of annulus crossings made by Tg+Caff mice when compared
to Tg mice. * = significantly greater than all other quadrants at p<0.01 and significantly
greater than Q2 for Tg group at p<0.025. ** = significantly different from Tg mice at
P<0.005.
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Circular Platform. In this task of reference learning/memory, there was an
overall groups effect over all eight days of testing [F(2,51)=7.66; P=0.001]. Post hoc
analysis indicated that Tg mice had significantly higher escape latencies overall
compared with NT and Tg+Caff mice (p<0.005; Fig. 11). Additionally, Tg escape
latencies were significantly higher than NT and Tg+Caff escape latencies on the last day
of testing (P<0.025 and P<0.001, respectively). Very similar group differences were
observed when the number of errors was analyzed (data not shown). For all animals,
there was an overall training (days) effect [F(7,357)=37.33; p<0.00001], indicating that
all animals collectively improved their performance across days despite the impaired
performance of Tg mice. Thus, the otherwise certain impairment of APPsw mice in the
circular platform task, evident in both their escape latencies and error making, was
prevented by the long-term administration of caffeine.
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Figure 11. Circular platform performance. Tg mice were significantly slower in
locating the escape hole over the eight days of circular platform testing, while Tg+Caff
mice performed similarly to NT mice. † = Tg mice significantly higher escape latencies
than both other groups at p<0.01 or higher level of significance.
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Platform Recognition. In platform recognition testing, an overall groups effect
was present [F(2,49)=7.44; p<0.002], with post hoc analysis revealing that Tg mice had
significantly higher escape latencies than NT mice (P<0.0005; Fig. 12). By contrast,
Tg+Caff mice performed at the same level as NT mice and nearly had lower overall
escape latencies compared to Tg mice (p=0.065). The benefits of caffeine administration
were evident even on the second day of testing and were profound by the last two days of
testing (Fig. 12) in that Tg+Caff mice performed identically to NT mice and significantly
better than Tg mice on both of those final days. A strong group by day interaction was
present [F(6,147)=4.14; p<0.001] due to the poor performance of the Tg group relative to
the other two groups. The apparent difficulties that Tg mice have in switching between
the spatial (cued) strategy used in Morris water maze to a search/recognition strategy in
the platform recognition task are reflected in their high escape latencies. In sharp
contrast, the long-term administration of caffeine protected against this “strategy
switching” impairment.
RAWM. For RAWM statistical analysis, data was evaluated across three 3-day
blocks for T1 (semi-randomized initial trial), T4 (final acquisition trial), and T5 (delayed
retention trial). The beneficial effects of caffeine on working memory were immediately
evident in block 1 of testing (Fig. 13). Tg+Caff mice were similar in performance to NT
controls and already better than Tg mice (p<0.05) during T4, while Tg mice were
impaired during both T4 (p<0.0001) and T5 (p<0.00001). In blocks 2 and 3 of testing,
Tg mice had significantly higher escape latencies during working memory trials T4 and
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Figure 12. Platform recognition performance over four days of testing. By the third
and fourth day of testing, performance of Tg+Caff mice was identical to NT mice and
much better than Tg controls. * = Tg and Tg+Caff mice significantly worse than NT
mice at p<0.05, † = Tg mice significantly worse than both NT and Tg+Caff mice at
P<0.05 or higher level of significance.
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Figure 13. RAWM performance over three 3-day blocks. During the first block of
testing, Tg mice had significantly slower escape latencies versus NT mice during T4 and
T5 (the trials indicative of working memory) while Tg+Caff mice were not different from
NT during T4. In the final two blocks of RAWM, Tg performance was significantly
higher in T4 and T5 than both NT and Tg+Caff mice, the later two groups being near
identical in performance. † = Tg mice significantly worse than both NT and Tg+Caff
mice at p<0.05 or higher level of significance. * = Tg and Tg+Caff mice significantly
different from NT mice at P<0.0001,
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T5 compared to NT and Tg+Caff mice (P<0.05 or higher levels of significance).
Tg+Caff mice, by contrast, were identical in working memory performance in
comparison to NT mice. A strong group by block interaction was present for T5
[F(4,98)=5.66; p<0.0005], which was clearly due to the much poorer T5 performance of
Tg mice compared to the other two groups. The consistent impairment of untreated
APPsw mice in T4 and T5 of RAWM testing indicate impaired working memory in these
mice, whereas the long-term administration of caffeine to APPsw mice offers protection
against working memory impairment.
The complete protection of working memory provided by caffeine is also
manifest in overall performance across all three blocks (Fig. 14). In overall T1
performance across all three blocks, Tg mice had significantly slower escape latencies in
comparison to NT mice (P<0.025) while Tg+Caff mice were nearly different from NT
mice (p=0.051). Escape latencies in overall T4 and T5 performance showed that Tg mice
were substantially impaired when compared to NT mice (p<0.00001), while Tg+Caff
mice were not different from NT mice and significantly better than Tg mice (p<0.005).
Additional support for impaired RAWM working memory in Tg mice was evident in by
their increased number of overall T4 and T5 errors made in comparison to NT controls
(p<0.0001 for both; data not shown). This impairment was also prevented by the longterm administration of caffeine, as Tg+Caff mice performed similarly to NT mice in
making significantly lower numbers of overall T4 and T5 errors compared to Tg mice
(p<0.0001 and p<0.005, respectively). There were no group differences in swim speed
present in RAWM testing, indicated by the number of seconds taken per arm choice
(latency/error ratio) for T4 and T5 combined.
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Figure 14. Overall RAWM performance. In working memory trials T4 and T5,
Tg+Caff mice performed identical to NT controls and were significantly better than Tg
control mice, indicating that the long-term administration of caffeine granted complete
protection against working memory impairment in RAWM testing. * = Tg mice
significantly higher latency than NT mice at P<0.025, † = Tg mice significantly worse
than both NT and Tg+Caff mice at P<0.005 or higher level of significance.
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Multi-metric Statistical Analysis
Factor Analysis. Factor analysis of behavioral measures was performed to
determine the underlying relationships between all of these measures (Table 3). FA
involving all 19 behavioral measures resulted in 13 of those measures loading on four
principal factors, which accounted for 61.2% of the total variance (a measure was
considered “significant” for loading on a factor if its component loading value exceeded
0.600 for that factor). All measures for RAWM, Morris maze acquisition, and platform
recognition loaded heavily in factor 1, thus this factor was considered the primary
cognition-based factor. The measures for activity and/or having an activity component
(open field, Y-maze entries, and circular platform errors) loaded into factor 2, while
circular platform latency loaded separately into factor 4 and balance beam loaded
separately into factor 5. No tasks loaded into factor 3.
Correlation Analysis. Correlation analyses were performed using all 19
behavioral measures and including all mice (Tg and NT). There were no correlations
between the string agility task and any of the cognitive tasks. Additionally, correlation
analysis revealed that the amount of time mice spent in the open arm of the elevated plus
maze correlated with an increased latency in multiple tasks (Morris maze, circular
platform, platform recognition, and RAWM). This may indicate that mice with decreased
anxiety are less motivated to escape certain tasks. As expected, there were numerous
inter-task correlations between measures in the three water-based. For measures taken
from the same task, strong intra-task correlations were also evident, particularly for
RAWM and Morris maze tasks.
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Table 3. Factor loadings of behavioral measures
Factor

All 19 behavioral measures

1

(32.61)
RM-T4-Fin
RM-T4
RM-T5-Fin
RM-T5
PR-Fin
PR-Avg
WM-Fin
WM-Avg

2

(13.97)
OF
CP-Err
YM-Ent

3

(10.10)
N/A

4

(8.247)
CP-Lat

5

(6.37)
BB

Numbers in bold type indicate percent of total variance explained by a given factor.
Abbreviations: BB, balance beam; CP-Err, circular platform overall errors; CP-Lat,
circular platform overall latency; OF, open field lines crossed; PR-Avg, Platform
recognition overall average; PR-Fin, Platform recognition final day average; RM-T4,
radial arm water maze latency overall T4; RM-T5, radial arm water maze latency overall
T5; RM-T4-Fin, radial arm water maze latency last block T4; RM-T5-Fin, radial arm
water maze latency last block T5; WM-Avg, water maze latency overall average; WMFin, water maze latency last day; YM-Ent, Y-maze entries.
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Discriminant Function Analysis. DFA was utilized to determine if multiple
behavioral measures could distinguish the three groups (NT, Tg, Tg+Caff) from one
another (Table 4). The “direct entry” DFA method (which includes all behavioral
measures) and the “stepwise forward” DFA method (which selects behavioral measures
from the total number evaluated based on their contribution to the variance) were used in
this analysis. Direct entry DFA, using all 19 behavioral measures, was very effective in
completely discriminating between all three groups (rank order of performance was NT >
Tg+Caff > Tg). Additionally, the stepwise forward DFA (using all 19 behavioral
measures) was also very effective in completely discriminating between all three groups
(P<0.0001). For the stepwise forward DFA, five behavioral measures were retained as
providing maximal discriminability: three cognitive-based measures (RAWM overall T4
latency, Morris maze retention, and circular platform overall latency) and two
sensorimotor measures (Y-maze entries and elevated platform time in open arms).
Additional DFAs were performed using only the eight cognitive-based measures
that loaded on factor 1 in FA (see Table 3). Both direct entry and stepwise forward DFAs
(using these eight cognitive-based measures) were able to completely discriminate
between all three groups. Six measures (three from RAWM, two from platform
recognition, and one from Morris maze) providing the maximal discrimination between
NT, Tg, and Tg+Caff groups. Canonical plots of both the 19 and 8 measure stepwise
forward DFAs are shown in Fig. 15. DFA’s involving all 19 behavioral measures was
slightly better at correctly classifying individual animals into their treatment/genotypic
group (84-90% correct) compared to DFA’s involving the 8 cognitive measures in factor
1 (75-79%).
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a

Table 4. Summary of discriminant function analyses
Measures

Direct Entry Method
Significance % Correct

Stepwise-forward method
Significance % Correct

All 19

P<0.0001

90%

P<0.0001

84%

RM-T4
WM-Ret
CP-Lat
YM-Ent
EP-TO

Factor 1
(Eight cognitive measures)

P<0.0001

79%

P<0.0001

75%

RM-T4
RM-T5
RM-T4-Fin
WM-Avg
PR-Fin
PR-Avg

a

Measures
Retained

P-values are from Wilks's λ. Post hoc analysis revealed complete discrimination between groups.
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Fig. 15. Canonical score plots of stepwise-forward DFAs used to compare the
“overall” cognitive performance of the three mouse groups. Each symbol represents
the cognitive performance of one animal graphed from the two linear functions derived in
the DFA. In both DFAs, all three groups could be completely distinguished from one
another.
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Neuropathologic/Neurochemical Measures: Study A
Adenosine Receptor Measures. Adenosine A1 and A2A receptor densities from
striatum, hippocampus, and frontal cortex from mice in Study A were analyzed using
western blotting (Fig. 16). No group differences in adenosine A1 receptors were seen in
striatum or hippocampus, but Tg and Tg+Caff mice both had significantly higher levels
of A1 receptors in the frontal cortex compared to NT mice (p<0.05). Furthermore, no
group differences were seen in adenosine A2A receptors in striatum or frontal cortex, but
Tg mice had significantly higher levels of A2A receptors in the hippocampus versus NT
mice (p<0.05).
The mRNA levels for A1 and A2A adenosine receptors were also analyzed in the
corresponding areas using RT-PCR. This evaluation revealed no significant group
differences in A1 receptor mRNA expression in striatum, hippocampus, or frontal cortex.
A2A receptor mRNA expression was below detectable levels in frontal cortex and
hippocampus, while in the striatum no group differences were qualitatively found in A2A
receptor expression.

Αβ (1-40) and (1-42) Analysis. Shortly following completion of behavioral
testing in Study A at 9 months of age (and approximately 4 months into long-term
caffeine administration), Aβ analysis by ELISA was performed on hippocampus tissues
(Fig. 17). Long-term administration of caffeine resulted in significant reductions of both
soluble Aβ1-40 (↓37%) and insoluble Aβ1-42 (↓32%). From this data, it is clear that the
long-term administration of caffeine has an impact on brain Aβ production and/or
clearance.
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Figure 16. Adenosine A1 and A2A receptor densities in the striatum, hippocampus,
and frontal cortex (Study A). The long-term administration of caffeine had no effect
on A1 receptors in any areas of the brain examined, although a transgenic effect of
increased A1 receptor density in the frontal cortex was observed. A further transgenic
effect was seen with A2A receptor densities increased in hippocampus of Tg mice, with
caffeine administration reducing this effect below significance. * = significantly different
from NT at p<0.05.
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Figure 17. Quantification of soluble/insoluble Aβ 1-40 and Aβ1-42 in hippocampus of
behaviorally tested APPsw mice (Study A). Caffeine-treated mice had significantly
reduced soluble Aβ 1-40 and insoluble Aβ 1-42 levels when compared to untreated Tg mice.
* Tg+Caff mice significantly lower versus Tg mice at p<0.05.
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Comparison of β- and α- CTFs. To elucidate any changes in α- and/or βsecretase activity in combined frontal and posterior cortex tissue from behaviorally-tested
mice of Study A, β-, and α-CTFs (carboxyl-terminal fragments) were analyzed by
western blotting (Fig. 18). Qualitative assessment of the resultant gel revealed the same
six Tg+Caff mice tested in the Aβ ELISA all had twice the β-CTF blot intensity of their
α-CTF blot intensity (2 to 1 ratio), whereas the same six Tg control mice from the Αβ
ELISA had more mixed blot intensities that leaned towards an even ratio between the two
CTFs (1.33 to 1 ratio). Using a non-parametric Mann-Whitney test showed the difference
between these group in CTF ratio was statistically significant (p<0.025). This data
implies that caffeine has an impact on the amyloidogenic processing of APP. In NT mice,
cortical levels of β− CTF’s were below the limits of detection.
Neuropathologic/Neurochemical Measures: StudyB

Αβ (1-40) and (1-42) Analysis. An 18-day administration of caffeine to aged 17
month old APPsw mice (Study B) resulted in a significant reduction of insoluble Aβ1-42
(↓30%) in the hippocampus (Fig. 19).
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Figure 18. Comparison of β-CTF to α- CTFs ratio in APPsw mice following longterm caffeine administration (Study A). Caffeine-treated mice had a significantly
greater ratio compared to untreated Tg mice, consistent with a shift in amyloidogenic
processing. * Tg+Caff mice significantly higher versus Tg mice at p<0.025.

96

Soluble Aβ 1-42

3000

35

2500

30

2000

25

1500

pmol/g

pmol/g

Soluble Aβ 1-40

*

1000

20
15
10

500
0

5
0

Tg Tg+Caff

Insoluble Aβ 1-42

Insoluble Aβ 1-40
12000

50000

10000

pmol/g

pmol/g

40000
30000
20000
10000
0

Tg Tg+Caff

8000

*

6000
4000
2000
0

Tg Tg+Caff

Tg Tg+Caff

Figure 19. Quantification of soluble/insoluble Aβ 1-40 and 1-42 in hippocampus of aged
APPsw mice (Study B). Caffeine-treated mice had significantly reduced insoluble Aβ142 levels compared to untreated Tg mice. * Tg+Caff mice significantly lower versus Tg
mice at p<0.05.
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Determination of γ-secretase Activity. To more fully determine if a reduction in
γ-secretase activity is involved in the reduction of amyloidogenic processing after
caffeine administration, combined frontal and posterior cortex tissue from the mice in
Study B were used to determine enzymatic activity of the γ-secretase class of proteases
using a fluorometric reaction. There were no significant group differences between
Tg+Caff and Tg mice (Fig. 20). However, γ−secretase activity in Tg+Caff mice was
comparable to NT mice, with both of these groups having slightly reduced γ−secretase
activity (È10%) when compared to untreated Tg mice. It is possible that endogenous
mouse secretase activity, unaffected by caffeine treatment, may be present and masking
any actual reductions in harmful γ-secretase activity that may have been provided by
caffeine treatment. Regardless, even slight reductions in γ-secretase activity might have
beneficial effects on amyloidogenic processing, as evident by caffeine’s ability to reduce
hippocampal Aβ levels in these same animals.
SAM Quantification. To determine if long-term administration of caffeine has an
impact on SAM (S-adenosyl-methionine) levels, combined frontal and posterior cortex
tissue from the mice in Study B were used in a SAM fluorescence assay (Mediomics,
LLC). There was no significant group difference between the Tg+Caff and Tg mice (Fig.
21), yet SAM concentrations were 49% higher in the Tg+Caff mice (7.89 µM) than the
Tg mice (5.30 µM). These results suggest that this analysis should be repeated, but next
time using a greater number of samples and a more precise technique in the micromolar
ranger.
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Figure 20. Gamma- Secretase activity in cerebral cortex of APPsw mice following
caffeine administration (Study B). Caffeine treatment did not significantly affect γsecretase activity in our assay. Although it is possible that endogenous mouse secretase
activity, unaffected by caffeine treatment, may be present and masking any actual
reductions in harmful γ-secretase activity.
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Figure 21. SAM (S-adenosyl-methionine) levels in cerebral cortex of APPsw mice
following caffeine administration (Study B). There were no significant group
differences in SAM concentrations following the caffeine treatment.
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Extracellular Adenosine Analysis. The left brain hemispheres from the aged
APPsw mice used in Study B were analyzed for adenosine levels by mass spectrometry
utilizing an ion-trap Finnegan LC-MS (Fig. 22). Interestingly, Tg mice had significantly
reduced extracellular brain adenosine levels (↓27%) compared to age-matched NT
(p<0.005). By contrast, Tg+Caff mice had extracellular brain adenosine levels that were
similar to NT mice and significantly higher than Tg mice (p<0.05 for Tg vs. Tg+Caff
comparison). These results suggest Tg mice have pathologically lowered extracellular
adenosine levels and caffeine administration restores those levels to normal.
Correlation Analyses involving neurochemical/neuropathologic measures.
Correlation analyses were performed between all 19 behavioral measures and the
four measures of Aβ (e.g., soluble and insoluble Aβ1-40, Aβ1-42) for all Tg mice. Other
than significant correlations between circular platform impairment and both soluble and
insoluble Aβ1-42, no significant correlations were found between the various forms of
quantified Aβ and any of the other behavioral tasks. As expected from the data presented
in Figures 16 and 20 involving aged Tg mice, a correlation was found between elevated
adenosine levels and decreased levels of insoluble Aβ1-42 (r=0.856; p=0.03) within the
hippocampus.
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Figure 22. Quantification of extracellular brain adenosine levels in Aged Mice
(Study B). The administration of caffeine resulted in a significant elevation of
extracellular adenosine levels in Tg+Caff mice to near that of NT mice, while untreated
Tg mice had significantly reduced levels. ** = significantly lower than NT (p<0.005)
and Tg+Caff mice (p<0.05).
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VII. Discussion
General Summary
In the present study, we determined behavioral and pathological changes in AD
transgenic mice mediated by the long-term administration of caffeine to APPsw transgenic
mice. The 4-month, daily administration of approximately 1.5 mg of caffeine to each
mouse, equivalent to about five cups of coffee in humans, resulted in global protection
against cognitive impairment. This behavioral protection was associated with reductions
in both soluble and insoluble forms of Aβ in hippocampus, supporting other reports that
cognitive impairment is Aβ dependent. Furthermore, an 18-day administration of caffeine
to aged APPsw mice also led to reductions in Aβ, and normalized the otherwise decreased
extracellular brain adenosine levels in untreated APPsw control mice. Importantly, results
from this study establish a direct link between long-term caffeine usage and the
SAM/SAH cycle, which when potentially disrupted in AD, has crucial implications in
APP processing and specifically gamma-secretase activity.
The complete cognitive protection and reductions in AD-like pathology found in
this study, together with the recent epidemiological study indicating a reduced risk of
Alzheimer’s disease from moderate caffeine use (Maia and Mendonca, 2002), provide a
compelling argument for future use of caffeine-based treatments in clinical trials to
protect against AD. Given the already widespread use and acceptance of caffeine and the
lack of serious side effects associated with long-term intake of caffeine in moderate
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amounts, it would be advisable to include a moderate, sustained daily caffeine intake
throughout life as a preventative against AD.
Behavioral Measures. Caffeine administration protected Tg mice against
cognitive impairment across tasks testing multiple cognitive domains (reference
learning/memory, working memory, recognition/identification, strategy switching). The
global protection afforded by chronic caffeine administration was not only evident in
every task wherein impairment was present in Tg mice, but also inclusive of all cognitive
tasks, as discriminant function analysis clearly showed. These wide-ranged cognitive
benefits of caffeine administration did not involve significant side-effects on
sensorimotor function that impacted cognitive performance because there were no
correlations between sensorimotor function and cognitive performance. A discussion of
results from each task, in the order performed, in presented below.
No differences in Y-maze alternations were seen between the three groups, thus it
is likely that the Y-maze task is not strict enough to detect any obvious abnormalities in
basic mnemonic processing in 8-9 month old APPsw mice as previous studies have shown
(Holcomb et al., 1999; King et al., 2002). Therefore, with no transgenic impairment
present, the long-term caffeine administration to transgenic mice was unable to have any
effect in this task.
Results from the acquisitional phase of Morris water maze revealed Tg mice had
significant impairment in the fourth and fifth blocks, indicating that these mice have
impaired spatial learning, as earlier studies have found (Hsiao et al., 1996; Westerman et
al., 2002; Arendash et al., 2004). Further impairment was seen in Tg mice in the memory
retention phase of this task, as these mice failed to show any preference for the quadrant
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formerly containing the submerged escape platform. In contrast, Tg mice given caffeine
had significantly quicker escape latencies during the acquisition phase of testing.
Additionally, Tg+Caff mice showed an exclusive preference for the quadrant formerly
containing the submerged escape platform, as indicated by their annulus crossings and
time spent in this particular quadrant. These results indicate the long-term administration
of caffeine protected APPsw mice against spatial/reference learning and memory
impairment.
Tg mice showed additional impairment in the circular platform task, a behavioral
task that also relies on spatial/reference learning and memory. In previous studies, Pompl
et al. (1999) reported seven month old APPsw mice were impaired in circular platform
performance when the escape hole’s location was changed (e.g., reversal learning). In
the present study, Tg mice were worse across all eight days of testing when compared to
NT mice in the circular platform task. By contrast, Tg+Caff mice performed identically
to NT mice and substantially better than Tg controls in this task. Additionally, Tg mice
made significantly more errors than the other two groups on the last day of testing,
further highlighting the cognitive impairment that the Tg group alone had and the
protective affect of caffeine against this impairment. It is noteworthy that the circular
platform impairments evident in the present study’s APPsw mice were present without
changing the escape whole’s location, as was the case for Pompl et al. (1999).
If performed after the Morris maze task, the platform recognition task relies
heavily on the ability of mice to switch from the cued (spatial) strategy used in Morris
water maze to a search/recognition strategy. Difficulties doing this are associated with
higher escape latencies. Previous behavioral characterizations reported APPsw mice of
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similar age were impaired in this task (Hsiao et al., 1996; King et al., 2002; Arendash et
al., 2004). Tg mice showed an overall impairment in platform recognition testing
compared to NT controls, while Tg mice given caffeine performed equivalent to NT mice
overall. Moreover, on the last day of testing in this study, Tg mice had significantly
higher escape latencies when compared to both NT and Tg+Caff mice. Thus, chronic
caffeine administration resulted in protection of strategy switching abilities in Tg mice.
As the most sensitive of all the cognitive-based behavioral tasks in our test
battery, the RAWM task is proficient in elucidating working memory impairment in
transgenic mice. An earlier study reported 15 month old APPsw mice were impaired in
RAWM testing (Morgan et al., 2000), and Arendash et al. (2004) found recently that this
impairment is evident as early as 6.5 months of age. Consistent with both of these prior
studies, 8-9 month old Tg mice in the present study were impaired overall in both T4 and
T5 of RAWM (the trials indicative of working memory), as evident by significantly
higher escape latencies than NT mice. As with all other cognitive tasks wherein the Tg
group was impaired, Tg+Caff mice were protected against RAWM working memory
impairment in performing significantly better than Tg controls and no different from NT
mice. The similar performance between NT and Tg+Caff mice in this sensitive task
indicates that long-term caffeine treatment grants powerful protection against working
memory impairment in these Alzheimer’s transgenic mice.
Consistent with earlier characterizations of this APPsw mouse model (Holcomb et
al., 1999; King et al., 2002; Arendash et al., 2004; Leighty et al., 2004), no differences in
overall sensorimotor performance that might indicate a gross motor dysfunction were
seen in either Tg or Tg+Caff mice compared to NT controls. The absence of differences
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in the elevated plus maze between Tg and Tg+Caff mice shows that the long-term
administration of caffeine does not result in any anxiety-based side effects that could
explain the profound differences in cognitive performance between these two groups.
These results are consistent with an earlier study reporting the lack of anxiolytic
properties associated with long-term caffeine administration to rodents (Bhattacharya et
al., 1997).
In factor analysis, the loading of RAWM, platform recognition, and Morris water
maze measures into factor 1 led this factor to be dubbed the primary cognitive-based
factor. Furthermore, both the direct entry and the step-wise forward methods of
discriminant function analysis were able to completely discriminate between all three
groups when using all 19 behavioral measures, as well as only the cognitively-based
measures in factor 1. This indicates that the long-term administration of caffeine resulted
in an overall protection of cognitive function across multiple behavioral measures,
although the performance of NT mice across those multiple behavioral measures could
still be distinguished from that of Tg+Caff mice. Thus, multiple cognitive domains were
protected by caffeine treatment in Tg mice.
The consistently poor performances of untreated APPsw transgenic mice in four of
the five cognitive-based tasks used in the present study indicates that these particular
mice exhibit widespread cognitive deficiencies that negatively impact spatial
memory/learning, working memory, and recognition/identification in a manner similar to
that of early to moderate Alzheimer’s disease in humans. These impairments currently
reported are consistent with an earlier behavioral characterization of APPsw mice
involving the same transgenic colony (Arendash et al., 2004). Even more significant, the
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long-term administration of caffeine to Tg mice, presumably started before these mice
become cognitively impaired, resulted in a behavioral phenotype similar to that of NT
mice. These results indicate caffeine’s potentially beneficial influences on the cognitivedestabilizing processes apparent in Alzheimer’s disease are worth investigating in a
clinical manner.
Previous studies investigating the behavioral effects of long-term caffeine
administration to normal (wild type) rodents form a consensus that this treatment has no
effects on cognition (Von Lubitz et al., 1993; Molinengo et al., 1994), although none of
these studies lasted beyond 15 days. Therefore, it is sufficient to assume that the
behavioral improvements seen in the caffeine-treated mice from the present study are a
result of behavioral protection against over-expression of the mutated APP gene in APPsw
mice, rather than a behavioral improvement resulting directly from caffeine’s immediate
effects on cognition. Furthermore, the present study aimed to duplicate moderate dietary
caffeine use in humans by placing mice on a truly long-term diet of caffeine
administration lasting for four months and continuing throughout behavioral testing, thus
establishing the mice are fully tolerant to caffeine and avoiding the potentially harmful
effects of caffeine withdrawal. By ensuring the mice consumed a caffeine dose equivalent
to approximately five cups of coffee in humans, the present study is the first of its kind to
closely mimic the nature of human caffeine consumption that was found to be associated
with a reduced risk of Alzheimer’s disease in a retrospective study (Maia and Mendonca,
2002).
Neurochemical/Neuropathological Measures. Long-term administration of
caffeine resulted in no significant effects on A1 adenosine receptor densities in the
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striatum, hippocampus, or frontal cortex of 9 month old, behaviorally-tested APPsw mice.
Untreated APPsw mice did have significantly increased A2A receptors in the hippocampus,
a finding that may indicate increased glial activation in this area as A2A receptors are
generally only associated with glial or vascular cells when found within the hippocampus
(Fiebach et al., 1996). Interestingly, caffeine administration did reduce these elevated
hippocampal A2A receptor levels to a level that was not statistically different than NT
mice, although the reduction was not great enough to result in a significant difference
between Tg and Tg+Caff mice. No differences in A1 or A2A mRNA expression were seen
following long-term caffeine administration in any of the groups in any of the brain areas
examined, as other labs have reported in normal, wild type mice (Johansson et al., 1993;
Shi and Daly, 1999).
The long-term administration of caffeine resulted in significantly less soluble Αβ140 and

insoluble Aβ1-42 in the hippocampi of caffeine-treated APPsw mice when compared

to the age-matched APPsw mice used in this study. Earlier characterizations of the APPsw
mice have indicated their behavioral impairment was Aβ dependent, as age-related
increases in amyloid levels (particularly the soluble isoforms) were found in the
hippocampus and/or associate cortices that coincided with deterioration in cognitive tasks
(Chen et al., 2000; Westerman et al., 2002). In the present study, reduced amyloid burden
thus appears to be a primary cause for the lack of impairment in cognition-based tasks
that the caffeine-treated APPsw mice exhibited. It is also noteworthy that the 18-day
administration of caffeine to 17.5 month old APPsw mice also resulted in a significant
reduction of insoluble Aβ1-42 in the hippocampus. This implies that caffeine
administration has an effect on amyloid levels after they have reached substantial
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amounts in aged APPsw mice, indicating long-term caffeine intake may have a treatment
role as well as a preventative role in Alzheimer’s disease.
The reductions in soluble Aβ1-40 and insoluble Aβ1-42 following caffeine treatment
are likely associated with changes in amyloidogenic processing, as caffeine is too small
molecularly to have an effect on binding to and clearing the much larger Aβ species. In
cerebral cortical tissues from behaviorally-tested Tg mice, the increased ratio between βand α-CTFs mediated by caffeine treatment thus suggests that caffeine has a direct
impact on the secretases involved in amyloidogenic processing. Increases in β-CTFs
could potentially be construed as a harmful precursor to Aβ generation that might result
from increases in β-secretase or decreases in α-secretase activity (as the β-CTF results
from β-secretase cleavage of APP and is the intermediate precursor that when cleaved by
γ-secretase cleavage yields Aβ). Yet in this case we theorize the increase in β-CTFs is a
result of decreased γ-secretase activity. Less γ-mediated cleavage of β-CTFs in the
caffeine-treated Tg mice would explain why they had a greater amount of β-CTF present
relative to α-CTF and would also explain the decreases in Aβ found in these mice.
When γ-secretase activity was assayed directly from cortical tissues of aged Tg
mice after 18 days of caffeine administration, no statistically significant difference in γsecretase activity was seen between Tg and Tg+Caff mice. However, there is the
possibility that a larger decrease in γ-secretase activity was masked by the presence of
other endogenous mouse proteins that are unaffected by caffeine treatment yet share γsecretase’s preferred substrate used in our assay.

110

In the present study, aged APPsw mice had significantly reduced brain levels of
extracellular adenosine, while the long-term (18 day) administration of caffeine restored
adenosine levels in aged APPsw mice to those of NT mice. Although mice were give ad
libum access to caffeine-treated water, it can generally be assumed that mice consume the
most water during nighttime hours and therefore plasma caffeine levels were likely
greatest during the night. In this study, mice were sacrificed at mid-morning, indicating
extracellular brain adenosine levels were significantly elevated hours after peak plasma
levels of caffeine have fallen. In a related finding, Conlay et al. (1997) found caffeine
administration to rats resulted in elevated plasma adenosine levels eight hours later.
Although it is likely caffeine transiently raises adenosine levels after increasing cellular
metabolism while increasing vasoconstriction in the brain, this effect should diminish as
caffeine is metabolized and its antagonism of adenosine receptors removed. The longer
duration of increased adenosine levels (i.e. eight hours after caffeine administration) thus
may be a result of increased S-adenosyl-homocysteine (SAH) hydrolysis, resulting in the
freeing of intracellular adenosine.
This potential link between caffeine administration and increased SAH hydrolysis
suggests that caffeine may have an impact on the impaired SAM/SAH cycle in
Alzheimer’s disease (see Figure 2), which has been shown through in vitro studies to
affect PS1 and BACE expression (Fuso et al., 2005). Decreases in SAM (S-adenosylmethionine) concentrations have been reported in AD patients (Morrison et al., 1996),
while SAH levels are found to be increased in AD patients (Kennedy et al., 2004). In the
present study, we found caffeine treatment raised SAM levels by 49% compared to
untreated Tg mice. Although this increase was not statistically significant, possibly due
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to either small group sizes (n=3) or euthanasia at a time well after maximal drinking (e.g.,
caffeine intake) , the data suggest caffeine raises SAM levels, leading to decreased
expression of PS1 and BACE and subsequent decreased production of Aβ (see Figure 3).
Proposed Mechanism of Caffeine-Mediated Cognitive Improvement
The leading theory in Alzheimer’s research is the amyloid hypothesis, which
proposes that an increased production of β-amyloid is responsible for a cascade of NFT
formation, oxidative damage, neuroinflammation, and neurodegeneration/neuronal
dysfunction. Supporting this theory, transgenic mice overexpressing a hAPP gene with
amyloidogenic mutations over-express mutant APP, resulting in production of Aβ and
ensuing cognitive impairment. In the present study, long-term caffeine treatment reduced
Aβ and protected the mice from cognitive impairment.
A previous study investigating the potential neurprotective effects of caffeine was
limited to an in vitro investigation that failed to account for caffeine-mediated
physiological changes aside from the pharmological blockade of adenosine receptors
(Dall’Igna et al., 2003). These investigators reported that A2A receptor blockade by
caffeine in cultured rat cerebellum cells resulted in neuroprotection against β-amyloid
toxicity. Past literature suggests, however, that A2A receptors are limited to insignificant
numbers in cerebellum cells (Fredholm et al., 1999; Fisone et al., 2004). It is also known
that cerebellum cells are not normally subjected to high levels of β-amyloid until possibly
the very late stages of advanced Alzheimer’s disease. If caffeine-mediated blockade of
A2A receptors was neuroprotective, then this would also dictate that caffeine must be
present in the bloodstream at all times. The epidemiological study by Maia and
Mendonca (2002) reported that a caffeine intake of 199 mg/day (approximately two cups
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of coffee) reduced the risk of Alzheimer’s disease, indicating that a sustained presence of
caffeine is not required for caffeine’s protective affects on cognitive function. In the
present study, the nature of the long-term caffeine treatment was designed to closely
mimic the normal consumption of caffeine in a typical caffeine user. With this in mind,
the in vivo effects of long-term caffeine intake on the cognitive function and pathological
features of APPsw mice could be examined through the present controlled study, which
eliminated other potential variables over a protracted longitudinal treatment format.
Caffeine is derived from a biosynthetic pathway in tea leaves that begins with the
precursor S-adenosyl-methionine (SAM) (Koshiishi et al., 2001). SAM is a major methyl
donor in the brain and is involved in the methylation status of various genes including
PS1 and BACE (Fuso et al., 2005). Under normal circumstances, SAM is converted to
SAH by catechol-O-methyltransferase (COMT) while donating its methyl group and
SAH is rapidly hydrolyzed to adenosine and homocysteine. When homocysteine is
present in higher concentrations, such as AD, the equilibrium reaction proceeds in the
opposite direction and favors the formation of SAH from adenosine and homocysteine.
Elevations in SAH could potentially block the methylation reaction leading to increased
expression of PS1 and BACE (Scarpa et al., 2003), and would be evident by decreases in
extracellular adenosine as it is synthesized into intracellular SAH.
Elevated plasma levels of homocysteine are considered a strong independent risk
factor for AD (Seshadri et al., 2002), and it was recently reported that AD patients over
the age of 60 consumed significantly less dietary vitamin B6 and folate than controls
(Mizrahi et al., 2003). Vitamin B6 and folate are both required for the recycling of
homocysteine back to methionine, and homocysteine accumulates when these compounds
113

are present in insufficient quantities (Fuso et al., 2005). Dietary influences such as these,
as well as other genetic or physical alterations that might affect homocysteine
metabolism, result in accumulation of SAH and the subsequent state of hypomethylation
proposed in the genes implicated in AD (Scarpa et al., 2003). It is therefore relevant to
address the link between caffeine, SAM, and SAH in Alzheimer’s disease.
It is currently unknown how caffeine might raise SAM levels as this is the first
study to suggest that a caffeine-induced elevation in SAM occurs. It is possible caffeine
is directly metabolized back to SAM once absorbed into the body, as caffeine is a
downstream product of SAM biosynthesis in tea leaves. Another proposed theory relies
on caffeine down-regulating astrocytic metabolism by antagonizing A2A receptors in
these cells, which contain the majority of COMT present in the brain. The potential
inactivation of COMT in this manner would lead to a decrease in transformation of SAM
to SAH, promoting the methylation status of PS1 and BACE. On this note, COMT
inhibitors have been used to treat depression (a symptom of Alzheimer’s disease) and are
reported to decrease the L-dopa induced increases in homocysteine that accompany
Parkinson’s disease patients (Miller et al., 1997). It was also recently found that direct
activation of COMT stimulates homocysteine synthesis in astrocytes, which in turn
export homocysteine to neighboring neurons (Huang et al., 2005). A caffeine-mediated
inhibition of COMT-induced homocysteine synthesis would thus have beneficial
implications in a variety of diseases in addition to AD.
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Clinical Implications of Caffeine Administration Study Findings and Potential Future
Investigations
In and of itself, the near-complete protection against cognitive impairment
granted by the long-term administration of caffeine to APPsw mice warrants further
studies into the relationship between caffeine and Alzheimer’s disease. Furthermore, the
substantial decreases in Aβ following caffeine treatment provide evidence that caffeine
does have a positive effect (perhaps indirectly) on amyloidogenic processing that results
in behavioral improvements. The proposed link between a caffeine-induced change in the
SAM/SAH cycle and the effect this relationship potentially has on SAM methylation of
BACE and PS1 activity would be novel in providing a link between a dietary influence
and the genetics of Alzheimer’s disease. In addition to this proposed “indirect”
mechanism for caffeine affecting amyloidogenic pathways, it is possible that “direct”
effects of caffeine on neuronal amyloidogenic pathways are also present. In vitro
neuronal culture studies could determine if such direct affects are, indeed, part of the
beneficial mechanisms through which caffeine reduces brain Aβ levels and protects
cognitive function.
The suggested diminishment of PS1 expression following caffeine treatment has
potentially powerful repercussions. First, decreased PS1 expression following long-term
caffeine use would result in decreases in the pathological amyloidogenic processing
found in Alzheimer’s disease as suggested, but this decrease in expression would also not
result in a complete loss of function of the PS1 gene, sidestepping the potential harmful
effects that often accompany PS1 inhibitors. Secondly, the 18-day treatment of caffeine
used in study B of this investigation also resulted in a substantial decrease in Aβ as well,
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indicating that caffeine administration may serve as an effective treatment against those
already diagnosed with AD. Lastly, the use of caffeine is already widely accepted by the
global community and is cost effective. It has also been established that moderate use of
caffeine is unaccompanied by harmful side effects as long as caffeine intake is
maintained on a daily basis. Thus, it is a safe, naturally-occurring nutraceutic agent that
could have significant prophylactic and therapeutic value against AD, whether taken
alone or in combination with other AD therapeutics.
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